Document:

EX-10.1

 Exhibit 10.1 
 CERTAIN MATERIAL (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 CO-PROMOTION AGREEMENT 

by and between 

ZOGENIX, INC. 
 and 
 MALLINCKRODT LLC 

Dated as of June 6, 2012 

 EXECUTION COPY 

TABLE OF CONTENTS 

 

									
	 ARTICLE I - DEFINITIONS
	  	 	1	  
		
	 ARTICLE II - GRANT
	  	 	12	  
				
		 	 Section 2.1
	  	Grant of Promotion Rights	  	 	12	  
				
		 	 Section 2.2
	  	Performance Through Affiliates and Subcontracting	  	 	12	  
				
		 	 Section 2.3
	  	Retention of Rights	  	 	12	  
		
	 ARTICLE III - COORDINATION OF ACTIVITIES
	  	 	13	  
				
		 	 Section 3.1
	  	Establishment of Committees	  	 	13	  
				
		 	 Section 3.2
	  	Joint Steering Committee	  	 	13	  
				
		 	 Section 3.3
	  	Joint Product Team	  	 	13	  
				
		 	 Section 3.4
	  	Other Terms Applicable to Committees	  	 	14	  
				
		 	 Section 3.5
	  	Disputes	  	 	15	  
		
	 ARTICLE IV - PRODUCT PROMOTION
	  	 	16	  
				
		 	 Section 4.1
	  	Product Detailing by Mallinckrodt	  	 	16	  
				
		 	 Section 4.2
	  	Product Detailing by Zogenix	  	 	17	  
				
		 	 Section 4.3
	  	Representations to Customers	  	 	17	  
				
		 	 Section 4.4
	  	Staffing and Training	  	 	17	  

									
		 	Section 4.5	  	Promotional Materials; Speaker Events	  	 	18	  
				
		 	 Section 4.6
	  	Mallinckrodt Call List	  	 	20	  
				
		 	 Section 4.7
	  	Promotion Reports	  	 	20	  
				
		 	 Section 4.8
	  	Medical Inquiries	  	 	20	  
				
		 	 Section 4.9
	  	Trademarks	  	 	21	  
				
		 	 Section 4.10
	  	Product Website	  	 	22	  
		
	 ARTICLE V - CLINICAL, COMPLIANCE, AND REGULATORY AFFAIRS
	  	 	22	  
				
		 	 Section 5.1
	  	Regulatory Approvals	  	 	22	  
				
		 	 Section 5.2
	  	Compliance with Regulatory Requirements	  	 	22	  
				
		 	 Section 5.3
	  	Compliance	  	 	22	  
				
		 	 Section 5.4
	  	Communications with Regulatory Authorities	  	 	23	  
				
		 	 Section 5.5
	  	Product Complaints	  	 	24	  
				
		 	 Section 5.6
	  	Adverse Drug Experience Reports	  	 	24	  
				
		 	 Section 5.7
	  	Recalls or Other Corrective Action	  	 	25	  
				
		 	 Section 5.8
	  	Assistance	  	 	25	  
		
	 ARTICLE VI - MANUFACTURING AND SUPPLY; SALES; PRICING
	  	 	26	  
				
		 	 Section 6.1
	  	Obligations of Zogenix	  	 	26	  
				
		 	 Section 6.2
	  	Mallinckrodt Forecasts; Sample Forecasts	  	 	26	  
				
		 	 Section 6.3
	  	[***]	  	 	26	  
				
		 	 Section 6.4
	  	Sales; Pricing	  	 	27	  
				
		 	 Section 6.5
	  	Samples	  	 	27	  
				
		 	 Section 6.6
	  	Manufacturing Matters	  	 	28	  

  

	*** 	 Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to
the omitted portions. 

									
		
	 ARTICLE VII - COMPENSATION; RECORDKEEPING; AUDITS
	  	 	28	  
				
		 	 Section 7.1
	  	Service Fees and Adjustment Payments	  	 	28	  
				
		 	 Section 7.2
	  	Tail Payment	  	 	29	  
				
		 	 Section 7.3
	  	Maintenance of Records; Audits	  	 	29	  
				
		 	 Section 7.4
	  	Payments	  	 	31	  
		
	 ARTICLE VIII - TERM AND TERMINATION
	  	 	31	  
				
		 	 Section 8.1
	  	Term	  	 	31	  
				
		 	 Section 8.2
	  	Early Termination	  	 	31	  
				
		 	 Section 8.3
	  	Force Majeure	  	 	34	  
				
		 	 Section 8.4
	  	Effect of Termination	  	 	34	  
		
	 ARTICLE IX - REPRESENTATIONS AND WARRANTIES
	  	 	35	  
				
		 	 Section 9.1
	  	Representations and Warranties of Zogenix	  	 	35	  
				
		 	 Section 9.2
	  	Representations and Warranties of Mallinckrodt	  	 	37	  
				
		 	 Section 9.3
	  	Product Warranty	  	 	39	  
				
		 	 Section 9.4
	  	Zogenix Disclaimer	  	 	40	  
				
		 	 Section 9.5
	  	Mallinckrodt Disclaimer	  	 	40	  
		
	 ARTICLE X - INTELLECTUAL PROPERTY MATTERS
	  	 	40	  
				
		 	 Section 10.1
	  	Intellectual Property Prosecution and Maintenance	  	 	40	  
				
		 	 Section 10.2
	  	Ownership	  	 	40	  
				
		 	 Section 10.3
	  	Infringement	  	 	40	  

									
	 ARTICLE XI - INDEMNIFICATION; LIMITS ON LIABILITY
	  	 	41	  
				
		 	 Section 11.1
	  	Indemnification	  	 	41	  
				
		 	 Section 11.2
	  	Consequential Damages	  	 	43	  
		
	ARTICLE XII - CONFIDENTIALITY AND PUBLICITY	  	 	43	  
				
		 	 Section 12.1
	  	Proprietary Information	  	 	43	  
				
		 	 Section 12.2
	  	Disclosures Required by Law	  	 	43	  
				
		 	 Section 12.3
	  	Publicity	  	 	44	  
				
		 	 Section 12.4
	  	Survival	  	 	44	  
		
	ARTICLE XIII - NOTICES	  	 	44	  
				
		 	 Section 13.1
	  	Notices	  	 	44	  
		
	ARTICLE XIV - INSURANCE	  	 	46	  
				
		 	 Section 14.1
	  	Insurance	  	 	46	  
		
	ARTICLE XV - MISCELLANEOUS	  	 	46	  
				
		 	 Section 15.1
	  	Dispute Resolution	  	 	46	  
				
		 	 Section 15.2
	  	Headings	  	 	47	  
				
		 	 Section 15.3
	  	Severability	  	 	48	  
				
		 	 Section 15.4
	  	Entire Agreement	  	 	48	  
				
		 	 Section 15.5
	  	Amendments	  	 	48	  
				
		 	 Section 15.6
	  	Counterparts	  	 	48	  
				
		 	 Section 15.7
	  	Waiver	  	 	48	  
				
		 	 Section 15.8
	  	Force Majeure	  	 	48	  
				
		 	 Section 15.9
	  	Successors and Assigns	  	 	49	  

									
		 	 Section 15.10
	  	Assignment	  	 	49	  
				
		 	 Section 15.11
	  	Construction	  	 	50	  
				
		 	 Section 15.12
	  	Governing Law	  	 	50	  
				
		 	 Section 15.13
	  	Equitable Relief	  	 	50	  
				
		 	 Section 15.14
	  	Relationship Between Parties	  	 	51	  

 CO-PROMOTION AGREEMENT 

This Co-Promotion Agreement (this “Agreement”) is made as of June 6, 2012 (the “Effective Date”),
by and between Zogenix, Inc., a Delaware corporation (“Zogenix”), and Mallinckrodt LLC, a Delaware limited liability company (“Mallinckrodt”). Each of Zogenix and Mallinckrodt is referred to herein, individually, as
a “Party” and, collectively, as the “Parties.” 
 WHEREAS, Zogenix desires to collaborate with
Mallinckrodt in the co-promotion of the Product in the Territory (each as defined below), and Mallinckrodt desires to collaborate with Zogenix with respect to such co-promotion, all in accordance with the terms and conditions contained herein;

 NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants herein contained, the Parties hereto intending
to be legally bound hereby agree as follows: 
 ARTICLE I 

DEFINITIONS 
 As used in this Agreement, the following terms shall have the following meanings: 
 Section 1.1 “3PL” means a Third Party logistics provider. 
 Section 1.2 “Act” means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301, et. seq., as it may be amended or supplemented from time to time, and the rules,
regulations and requirements promulgated or issued thereunder or in connection therewith. 
 Section 1.3
“Adverse Drug Experience” means any “adverse drug experience” as defined or contemplated by 21 C.F.R. 312.32 or 314.80, as may be amended from time to time, associated with the use of the Product. 

Section 1.4 “Adverse Drug Experience Report” means any oral, written or electronic report of any Adverse
Drug Experience transmitted to any Person. 
 Section 1.5 “Affiliate” means, with respect to any
Person, any other Person that directly or indirectly controls, is controlled by or is under common control with, such first Person. For the purposes of this definition, “control” (including, with correlative meanings, the terms
“controlling,” “controlled by” and “under common control with”), as applied to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of
that Person, whether through the ownership of voting securities, by contract or otherwise. 
 Section 1.6
“Agreement” has the meaning set forth in the preamble to this Agreement. 

  
 1 

 Section 1.7 “[***]”means [***]***
during the Term [***]. 
 Section 1.8
“[***]” means the [***], and each successive [***] during the Term after the [***]. 
 Section 1.9 “[***]” means each [***] during the Term [***]. 
 Section 1.10 “Back Order Events” has the meaning set forth in Section 6.3(b). 
 Section 1.11 “Baseline Net Sales” means [***] of the Mallinckrodt Call List Dispensed Units for the [***] full months[***]. For clarity, the Baseline Net Sales shall
remain fixed for the Term. For clarity, Baseline Net Sales shall be calculated [***] using the then-applicable Mallinckrodt Call List. 
 Section 1.12 “Business Day” shall mean a day other than a Saturday or Sunday on which banking institutions in New York are open for business. 

Section 1.13 “cGMP” shall mean “current Good Manufacturing Practices” as such term is defined
from time to time by the FDA or any other relevant Governmental Authority having jurisdiction over the manufacture or sale of the Product pursuant to applicable regulations, guidelines or otherwise. 

Section 1.14 “Change of Control”, with respect to a Party, shall occur when: 

(i) any person or “group” (as such terms are defined below in this Section 1.14) is or becomes the
“beneficial owner” (as defined below), directly or indirectly, of shares of capital stock or other equity interests of such Party then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the
election of the directors, managers or similar supervisory positions (“Voting Stock”) of such Party representing [***] of the total voting power of all outstanding classes of Voting Stock of such Party; 

(ii) such Party enters into a merger, consolidation or similar transaction with another Person (whether or not such Party
is the surviving entity) and as a result of such merger, consolidation or similar transaction the Persons that beneficially owned, directly or indirectly, the shares of Voting Stock of such Party immediately prior to such transaction do not
beneficially own, directly or indirectly, shares of Voting Stock of the surviving Person representing at least [***] of the total voting power of all outstanding classes of Voting Stock of the surviving Person; 

(iii) such Party sells or transfers to any Third Party, in one or more related transactions, properties or assets
representing all or substantially all of such Party’s assets; or 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 2 

 (iv) the holders of capital stock or equity of such Party approve a plan or
proposal for the liquidation or dissolution of such Party. 
 For the purpose of this definition of Change of Control,
(A) “person” and “group” have the meanings given such terms under Section 13(d) and 14(d) of the United States Securities Exchange Act of 1934 and the term “group” includes any group acting for the purpose of
acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the United States Securities Exchange Act of 1934, (B) a “beneficial owner” shall be determined in accordance with Rule 13d-3 under the United
States Securities Exchange Act of 1934, and (C) the term “beneficially owned” and “beneficially own” shall have meanings correlative to that of “beneficial owner.” In no event shall the public spin-off of
Mallinckrodt and its Affiliates from Covidien plc, as publicly announced by Covidien plc in December 2011, constitute a Change of Control of Mallinckrodt for any purpose hereof. 

Section 1.15 “Claim” has the meaning set forth in Section 11.1(a). 

Section 1.16 “Commercial Officers” means the commercial heads of the branded pharmaceutical businesses of
Zogenix and Mallinckrodt (or their respective Affiliates), or the Chief Executive Officer of either Party, (or such other executive or senior officer of the Party or an Affiliate designated by the Chief Executive Officer of either Party) .

 Section 1.17 “Committees” has the meaning set forth in Section 3.1. 

Section 1.18 “Compliance Materials” has the meaning set forth in Section 5.3(b). 

Section 1.19 “Compliance Records” has the meaning set forth in Section 7.3(a)(i). 

Section 1.20 “Confidentiality Agreement” means that certain Confidentiality Agreement between Zogenix and
Mallinckrodt [***]. 
 Section 1.21 “Control” or “Controlled” means,
with respect to patents, know-how, data, information or other intellectual property rights of any kind, the possession by a Person of the ability to grant a license or sublicense in and to such rights without violating the terms of any agreement or
arrangement between such Person and any other Person. 
 Section 1.22 “Deductions” means, with
respect to a [***], the following deductions paid, incurred or accrued, applied in a consistent manner and (as applicable) calculated in accordance with GAAP (consistently applied): [***]. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 3 

 Section 1.23 “Demand Unit” means, with respect to a
particular period, the number of Units of Product [***] as measured by the Third Party Audit, [***] (e.g., for patient assistance). 
 Section 1.24 “Detail” means an in-person, face-to-face sales presentation of the Product made by a Sales Representative to a Professional. 

Section 1.25 “Direct Cost” means, as to a Party, that Party’s expenses [***].

 Section 1.26 “Effective
Date” has the meaning set forth in the preamble to this Agreement. 
 Section 1.27 “Enforcement
Action” has the meaning set forth in Section 10.3(b). 
 Section 1.28 “Expense
Records” has the meaning set forth in Section 7.3(a)(iv). 
 Section 1.29
“Expenses” [***]. 
 Section 1.30 “FDA” means the United States Food and
Drug Administration or any successor agency performing comparable functions in the Territory. 
 Section 1.31
“Force Majeure Event” has the meaning set forth in Section 15.8(a). 
 Section 1.32
“GAAP” means, as to any Party, generally accepted United States accounting principles as consistently applied by such Party. 
 Section 1.33 “Generic Drug Act” has the meaning set forth in Section 9.1(g). 
 Section 1.34 “Generic Product” means [***]. 

Section 1.35 “Governmental Authority” means any court, agency, authority, department, regulatory body or
other instrumentality of any government or of any national, federal, state, provincial, regional, county, city or other political subdivision of any such government, which has competent and binding authority to decide, mandate, regulate, enforce or
otherwise control the activities of the Parties contemplated by this Agreement. 
 Section 1.36 “Health
Care Provider” means any “health care provider,” as that term is used in the PhRMA Code. 

Section 1.37 [***] for which the Mallinckrodt Sales Representative becomes eligible based on [***].

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 4 

 Section 1.38 “Indemnified Party” has the meaning set forth
in Section 11.1(a). 
 Section 1.39 “Indemnified Person” has the meaning set forth in
Section 11.1(a). 
 Section 1.40 “Indemnifying Party” has the meaning set forth in
Section 11.1(a). 
 Section 1.41 [***]. 

Section 1.42 “Initial Sales Force Training Program” has the meaning set forth in Section 4.4(d).

 Section 1.43 “Initial Term” has the meaning set forth in Section 8.1. 

Section 1.44 “JAMS” has the meaning set forth in Section 15.1. 

Section 1.45 “JPT” has the meaning set forth in Section 3.1. 

Section 1.46 “JSC” has the meaning set forth in Section 3.1. 

Section 1.47 “Legal Requirements” means (i) the American Medical Association Guidelines on Gifts to
Physicians from Industry, (ii) the PhRMA Code, (iii) the Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers, dated April, 2003, (iv) the Act, (v) the Generic Drug Act, (vi) the PDMA,
(vii) the FDA’s applicable regulations and guidelines concerning the advertising of prescription drug products, and OPDP’s applicable promotional guidelines, and (viii) all federal, state and local laws, and the rules,
regulations, guidances, guidelines and requirements of all Governmental Authorities in effect from time to time applicable to the manufacture, Promotion, distribution, warehousing, handling and sale of the Product (including Samples) in the
Territory, including those governing price reporting, reimbursement, monetary disclosure, anti-kickback matters, false claims and equal employment and non-discrimination. 

Section 1.48 “Loss” has the meaning set forth in Section 11.1(a). 

Section 1.49 “Mallinckrodt” has the meaning set forth in the Preamble to this Agreement. 

Section 1.50 “Mallinckrodt Call List” means the mutually agreed list of approximately [***]
Professionals primarily practicing as general practice, family practice and internal medicine to be Detailed by the Mallinckrodt Sales Force. The 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 5 

 
Initial Mallinckrodt Call List has been prepared and exchanged by the Parties as of the Effective Date and is made binding hereunder; the Parties will work together in good faith to update such
Initial Mallinckrodt Call List no later than [***] days after the Effective Date. For clarity, during the Term the Mallinckrodt Call List may exceed [***] Professionals pursuant to [***] or pursuant to the procedures set forth
in Section 4.6. 
 Section 1.51 “Mallinckrodt Call List Dispensed
Units” means, with respect to a particular
[***], the number of [***] as measured by the Third Party Audit. For clarity, Units of Product [***], unless such Units (i) are [***], in which case [***], notwithstanding any
other procedures set forth herein, including those set forth in Section 3.2(b). 
 Section 1.52
“Mallinckrodt Compliance Materials” has the meaning set forth in Section 5.3(a). 
 Section
1.53 “Mallinckrodt Minimum Sales Effort” has the meaning set forth in Section 4.1(a). 

Section 1.54 “Mallinckrodt Net Sales” means, with respect to a particular [***], (a) the
product of (i) the Mallinckrodt Call List Dispensed Units for such [***], minus (ii) the Baseline Net Sales multiplied by (b) the applicable Net Selling Price for that [***]. 

Section 1.55 “Mallinckrodt Promotional Effort” has the meaning set forth in Section 4.1(a).

 Section 1.56 “Mallinckrodt Sales Force” means the field force of Sales Representatives
employed or contracted by Mallinckrodt. 
 Section 1.57 “Mallinckrodt Trademarks” means those
Trademarks owned or Controlled by Mallinckrodt or its Affiliates and identified in a Trademark Consent. 

Section 1.58 “Minimum Net Sales Threshold” has the meaning set forth in Section 8.2(c)(ii).

 Section 1.59 “NDA” means the “New Drug Application” (as such term is used under the
Act) with respect to the Product with reference number 22-239 that was submitted by Zogenix to the FDA on December 28, 2007 and approved by the FDA on July 15, 2009, and all subsequent submissions, supplements and amendments thereto.

 Section 1.60 “Net Sales” means, with respect to a particular [***], the gross invoiced
sales of Product to a Third Party in the Territory for that [***], less the Deductions for that [***]. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 6 

 Section 1.61 “Net Selling Price” means,
with respect to a particular [***], the quotient of (i) the Net Sales for the [***], divided by (ii) the number of Territory Invoiced Units for such [***]; provided, however, that the Net Selling
Price for the Initial [***] shall be [***]; provided further that the Net Selling Price shall be adjusted [***] for a subsequent [***] in the event that [***] applicable [***] as follows:
(x) for a [***] taken during [***], the applicable Net Selling Price shall be adjusted [***], (y) for a [***] taken [***], the applicable Net Selling Price shall be adjusted [***], and (z) for
a [***] taken [***], the applicable Net Selling Price shall be adjusted [***]. 

Section 1.62 “Net Sales and Financial Records” has the meaning set forth in Section 7.3(a)(vi).

 Section 1.63 “OPDP” means the FDA’s Office of Prescription Drug Promotion (formerly the
Division of Drug Marketing, Advertising and Communications or DDMAC), or any successor Governmental Authority performing comparable functions in the Territory. 
 Section 1.64 “Order” means any award, decision, injunction, judgment, decree, order, ruling, or verdict entered, issued, made or rendered by any Governmental Authority or by any
arbitrator. 
 Section 1.65 “Paragraph IV Notice” has the meaning set forth in
Section 10.3(a). 
 Section 1.66 “PDMA” means the Prescription Drug Marketing Act, as
amended, and the rules and regulations promulgated thereunder. 
 Section 1.67 “Person” means
any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, or other entity or Governmental Authority.

 Section 1.68 “PhRMA Code” means the PhRMA Code on Interactions with Healthcare Professionals
(revised as of July 2008 and as it may be further revised or supplemented from time to time). 
 Section 1.69
“PIR” or “Product Information Request” has the meaning set forth in Section 4.8. 
 Section 1.70 “Prescriber Level Data” means [***] during a specified time period. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 7 

 Section 1.71 “Product” means Sumavel DosePro needle-free
delivery system (sumatriptan injection 6mg/0.5mL), or such other formulations or dosage strengths of such product which Zogenix may introduce for commercial sale during the Term, [***]. 

Section 1.72 “Product Complaint” means any written, electronic or verbal communication that alleges
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness or performance of the Product after the Product is released for distribution. 

Section 1.73 “Product Website” has the meaning set forth in Section 4.10. 

Section 1.74 “Professional” means a physician or other health care practitioner who is permitted by law
to prescribe the Product. 
 Section 1.75 “Promote,” “Promotional” and
“Promotion”, and any variants of any of the foregoing, mean those activities to be undertaken by either Mallinckrodt or Zogenix, as applicable, to encourage sales or appropriate use of the Product, including Details, sampling,
Detail aids, coupons, discount cards, journal advertising, direct mail programs, direct-to-consumer advertising, convention exhibits and other forms of marketing, advertising, public relations or promotional efforts. 

Section 1.76 “Promotion Commencement Date” means [***]. 

Section 1.77 “Promotion Records” has the meaning set forth in Section 7.3(a)(ii). 

Section 1.78 “Promotional Effort Reinstatement Date” has the meaning set forth in Section 4.1(g).

 Section 1.79 “Promotional Materials” has the meaning set forth in Section 4.5(a).

 Section 1.80 “Proprietary Information” means any proprietary and/or confidential information
communicated by or on behalf of one Party (or any of its Affiliates) to the other Party (or any of its Affiliates) in connection with or relating to this Agreement (including discussions and negotiations relating hereto), whether communicated prior
to, on or following the Effective Date, including the Technology and financial, marketing, business, technical and scientific information or data, information related to a Party’s compensation of its Sales Representatives, information contained
within any Commercial Plan, and the information exchanged pursuant to this Agreement, whether communicated in writing, orally or electronically. For the avoidance of doubt, the commercial data and information 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 8 

 
generated by each Party in connection with its activities under this Agreement are the Proprietary Information of that Party, the terms of this Agreement are the Proprietary Information of both
Parties, training materials provided by Zogenix to Mallinckrodt are the Proprietary Information of Zogenix and Compliance Materials of either Party are the Proprietary Information of that Party (in each case, subject to the exceptions set forth
below in this Section 1.80). Proprietary Information shall not include information that the receiving Party can show through written documentation: 
 (a) at the time of disclosure, is publicly known, 
 (b) after the
time of disclosure, becomes part of the public domain, except by breach of an agreement between the disclosing Party or any Affiliate thereof and the receiving Party or any Affiliate thereof, 

(c) is or was in the possession of the receiving Party or any Affiliate thereof at the time of disclosure by the
disclosing Party and was not acquired directly or indirectly from the disclosing Party or any Affiliate thereof or from any Third Party under an agreement of confidentiality to the disclosing Party or any Affiliate thereof, and 

(d) is or was developed by the receiving Party or its Affiliates without use of or reference to the other Party’s
Proprietary Information. 
 Section 1.81 “Regulatory Approval” means any and all consents or
other authorizations or approvals required from a Governmental Authority to market and sell the Product in the Territory. 
 Section 1.82 “Safety Stock” means, with respect to each [***], a quantity of the Product equal to [***] in the [***]. For purposes of determining the amount of Safety
Stock for an [***], Zogenix may include [***], in each case [***]. 
 Section 1.83
“Sales Force” means the Mallinckrodt Sales Force or the Zogenix Sales Force, as the case may be.

Section 1.84 “Sales Representatives” means sales representatives employed by Mallinckrodt or Zogenix (as
the case may be), or employed or contracted by a Third Party contracted by Mallinckrodt or Zogenix to provide sales representatives, to Detail the Product who have been trained and equipped to Detail the Product.

Section 1.85 “Sample Forecast” has the meaning set forth in Section 6.2(b). 

Section 1.86 “Sample Order” means a written purchase order in a form reasonably acceptable to both
Parties that sets forth, with respect to the period covered thereby, (i) the quantities of Samples to be delivered by Zogenix to Mallinckrodt and (ii) the required delivery dates therefor. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 9 

 Section 1.87 “Samples” has the meaning set forth in
Section 6.5(a). 
 Section 1.88 “Serious Adverse Drug Experience” means any “serious
adverse drug experience” as defined or contemplated by 21 C.F.R. 312.32 or 314.80, as it may be amended or supplemented from time to time, associated with use of the Product. 

Section 1.89 “Serious Adverse Drug Experience Report” means any Adverse Drug Experience Report that
involves a Serious Adverse Drug Experience. 
 Section 1.90 “Service Fee” has the meaning set
forth in Section 7.1(a). 
 Section 1.91 “Speaker Events” means peer-to-peer informational
programs in which a contracted healthcare professional presents Product-related medical or scientific information to a group of other Professionals. 
 Section 1.92 “Tail Payment” has the meaning set forth in Section 7.2. 
 Section 1.93 “Tail Period” has the meaning set forth in Section 7.2. 
 Section 1.94 “Technology” means all pharmacological, toxicological, preclinical, clinical, technical or other similar information, data and analysis and know-how relating to the Product
or the manufacture thereof, and all proprietary rights relating thereto owned or otherwise Controlled by Zogenix or its Affiliates; provided that, for clarity, commercial data and information generated by or for Mallinckrodt hereunder shall
not constitute Technology. 
 Section 1.95 “Term” means the Initial Term and any automatic
extension period as provided in Section 8.1. 
 Section 1.96 “Territory” means the United
States, excluding Puerto Rico and the other territories and possessions of the United States. 
 Section 1.97 “Territory Invoiced Units” means, with respect to a particular [***], the number of [***]. 

Section 1.98 “Third Party” means any Person other than Mallinckrodt or Zogenix or their respective
Affiliates. 
 Section 1.99 “Third Party Audit” means the Third Party audit known currently as
[***] (or such other Third Party data source as the Parties may agree upon from time to time). [***]. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 10 

 Section 1.100 “Timely Supply” means (i) with respect
to [***], the delivery by Zogenix of such [***] by [***] and (ii) with respect to [***], the [***] of such [***]. 

Section 1.101 “Trade Demand” means, with respect to any period, the aggregate number
of [***] during such period by [***].

 Section 1.102 “Trademark” means, as to any Party, any trademark, trade dress, service mark,
trade name, brand name, corporate name, logo, business symbol, or any other source identifying word, slogan, symbol or design, or any combination thereof, whether registered or unregistered, or any registration and application therefor or any
renewal of such registration. 
 Section 1.103 “Trademark Consent” has the meaning set forth in
Section 4.9(b). 
 Section 1.104 “Training Records” has the meaning set forth in
Section 7.3(a)(iii). 
 Section 1.105 “Unit” means a single dose of Product. 

Section 1.106 “United States Bankruptcy Code” means the U.S. Bankruptcy Code, 11 U.S.C. §§ 101,
et seq. 
 Section 1.107 “Vacancy” means, with respect to a Sales Force, a vacancy in the
position of a Sales Representative included or contemplated to be included in the Sales Force or other sustained unavailability of such a Sales Representative to Detail the Product for any particular period of time. 

Section 1.108 “Volume Records” has the meaning set forth in Section 7.3(a)(v). 

Section 1.109 “[***]” means the [***]. 

Section 1.110 “Zogenix” has the meaning set forth in the preamble to this Agreement. 

Section 1.111 “Zogenix Call List” means the list of Professionals Detailed by the Zogenix Sales Force for
any specific period of time. 
 Section 1.112 “Zogenix Compliance Materials” has the meaning set
forth in Section 5.3(b). 
 Section 1.113 “Zogenix Sales Force” means the field force of
Sales Representatives employed or contracted by Zogenix. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 11 

 Section 1.114 “Zogenix Supply Failure”
shall be deemed to have occurred if, in any [***], Zogenix fails to meet, in (i) at [***] or (ii) any [***],[***] of the actual [***] for the Product. 
 Section 1.115 “Zogenix Trademarks” means the Trademarks consisting of (i) Sumavel®, (ii) DosePro®, (iii) Zogenix® and (iv) such other Trademarks owned or
Controlled by Zogenix that are used in any manner in connection with the Product, and, in each case, all related domain names and other trademark related rights. 
 ARTICLE II 
 GRANT 

Section 2.1 Grant of Promotion Rights 

During the Term, subject to and in accordance with the terms and conditions of this Agreement, Zogenix hereby grants to Mallinckrodt and
Mallinckrodt hereby accepts a co-exclusive (with Zogenix) right to Promote the Product to Professionals on the Mallinckrodt Call List under the Zogenix Trademarks in the Territory. 

Section 2.2 Performance Through Affiliates and Subcontracting 

No Party may assign, subcontract, or otherwise transfer or delegate any of its rights or obligations under this Agreement without the
express written permission of the other Party, which consent may be withheld by the other Party in its sole discretion, except that: (i) either Party may transfer, assign, or delegate such rights or obligations pursuant to Section 15.10
and (ii) without the other Party’s consent, (A) either Party may perform any or all of its obligations and exercise any or all of its rights and licenses under this Agreement through any of its Affiliates; provided, however,
that such Party shall remain responsible for the performance of its obligations under this Agreement, (B) subject to Sections 4.1(c) and 4.1(d), either Party may subcontract with one or more Third Parties to provide Sales Representatives to
Detail the Product and (C) Zogenix may subcontract or sublicense to one or more Third Parties its right and obligation to manufacture the Product hereunder. 

Section 2.3 Retention of Rights 
 Zogenix retains and shall retain all proprietary and property interests in the Product until the point of sale or, in the case of Samples, until delivered to Mallinckrodt as contemplated by
Section 6.5. Mallinckrodt shall not have nor represent that it has any control or proprietary interest or property interests in the Product, except for the rights and licenses granted hereunder. Except as expressly set forth herein, nothing
contained herein shall be deemed to grant Mallinckrodt a license or other right or interest in any patent, Trademark or other similar property of Zogenix or its Affiliates. Except as expressly set forth herein, nothing contained herein shall be
deemed to grant Zogenix a license or other right or interest in any patent, Trademark or other similar property of Mallinckrodt or its Affiliates. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 12 

 ARTICLE III 
 COORDINATION OF ACTIVITIES 
 Section 3.1
Establishment of Committees 
 Within [***] days after the Effective Date, the Parties agree to establish, in each
case for the purposes specified herein, (i) a Joint Steering Committee (the “JSC”) and (ii) a Joint Product Team (“JPT”, and collectively with the JSC, the “Committees”)). The Parties
acknowledge and agree that none of the Committees has the power to amend, modify or waive any of the terms or conditions of this Agreement. 
 Section 3.2 Joint Steering Committee 
 (a) The JSC shall be
established by the Parties and shall be made up of an equal number of representatives from each Party. Initially, the JSC shall have [***] members, [***] of whom shall be appointed by Zogenix in its sole discretion, and [***] of
whom shall be appointed by Mallinckrodt in its sole discretion. 
 (b) The JSC shall have the following responsibilities:
(i) reviewing and discussing commercial strategy for the Product in the Territory, (ii) if Zogenix determines to submit any such changes to the JSC for its approval, (A) reviewing and approving (or not) any changes to [***] to
take effect during the Term, (B) reviewing and approving (or not) material changes to [***], and (C) [***], (iii) reviewing and discussing [***] to the extent such revisions would materially [***] otherwise
materially [***], (iv) reviewing and approving changes to the Professionals listed on the Mallinckrodt Call List, as necessary, (v) overseeing the work of the JPT, receiving and reviewing reports and other information submitted by
the JPT and resolving all disputes referred to it by the JPT, [***] and (vii) making such other decisions as may be delegated to the JSC pursuant to this Agreement or by written agreement of the Parties from time to time. 

(c) Notwithstanding the foregoing, (i) the JSC has no authority to make decisions with respect to matters that relate to the
development of or Regulatory Approval for the Product, (ii) the JSC has no authority to require a Party to engage in Promotion activities beyond those obligations set forth in Article IV, and (iii) the JSC has no authority to amend or
supplement this Agreement in any way or to permit or deny the right to any Party to take any action permitted hereunder except as expressly set forth in the preceding provisions of this Section 3.2. 

Section 3.3 Joint Product Team 
 The JPT shall be established by the Parties and shall be made up of an equal number of representatives of each Party. Initially, the JPT shall have [***] members, [***] of whom shall be
appointed by Zogenix in its sole discretion, and [***] of whom shall be appointed by Mallinckrodt in its sole discretion. The JPT shall have the following responsibilities: (i)

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 13 

 
facilitating collaboration between the Parties on all Product sales and marketing strategies and programs in the Territory, including matters relating to managed care and trade,
(ii) proposing changes to the Professionals listed on the Mallinckrodt Call List to the JSC, as necessary, and (iii) making such other decisions as may be delegated to the JPT pursuant to this Agreement or by written agreement of the
Parties from time to time.  
 Section 3.4 Other Terms Applicable to Committees 

(a) Subject to Section 3.5, decisions of each Committee shall be made by agreement between the representatives
of Mallinckrodt, and the representatives of Zogenix, with each Party having one (1) vote. For the avoidance of doubt, each Party shall have an equal voice in decision-making, regardless of the number of representatives of that Party present or
voting. No decision of a Committee shall be valid unless each Party is represented by at least [***] members at the meeting at which the decision is made. The Parties shall cause their respective representatives on each Committee to use
their good faith efforts to resolve all matters appropriately presented to them in an expeditious manner. 
 (b) A Party
may change any of its representatives at any time by giving written notice to the other Party. The total number of members on a Committee may be changed by agreement of the Parties from time to time, provided that each Party has the
right, in its sole discretion, to appoint an equal number of members to the Committee. The members appointed to the Committee by each Party shall be employees of such Party and shall have the requisite experience and seniority to make decisions on
behalf of such Party with respect to issues falling within the jurisdiction of the Committee; provided that either Party may appoint non-employee legal representatives or consultants to serve as members of the JPT (but not the JSC) with the
prior written consent of the other Party, such consent not to be unreasonably withheld. 
 (c) The chair of each Committee will
be an employee of Zogenix. The chair of a Committee shall have the authority and responsibility to call meetings of the Committee, to propose agendas for (and any other member of the Committee may add items to such agendas) and preside over
such meetings, and to appoint a secretary to record minutes for such meetings. The chair shall have no tie-breaking vote, or (except as set forth in the immediately preceding sentence) any other authority or power beyond those of the other members
of the Committee. 
 (d) Meetings of any Committee may be called by the chair of the Committee from time to time and, upon no
less than [***] days’ notice, shall otherwise be called when requested by a Party; provided, however, that (i) the JSC shall meet at least [***], and no less than [***] thereafter, and otherwise as required to
resolve disputes and (ii) the JPT shall meet at least [***] and at least [***]. Meetings may be held in person or by video or telephone conference. Unless otherwise agreed, the location of in-person meetings shall
alternate between the corporate offices of the Parties. The format of the meetings and all other procedural matters shall be decided by the Committee. Minutes of a Committee meeting shall be circulated to the 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 14 

 
Parties by the secretary promptly following the meeting for review and comment. Each Party shall bear its own travel and related costs incurred in connection with participation in the
Committees. 
 (e) Communications among members of a Committee in connection with the conduct of the day-to-day business of the
Committee shall not be subject to the notice provisions set forth in Section 13.1, but shall be governed by the communications protocol agreed upon unanimously by the members of the Committee; provided, however, that any notice relating
to disputes with respect to matters arising under the jurisdiction of the Committee (or otherwise) shall be provided pursuant to Section 13.1. 
 Section 3.5 Disputes 
 The Parties shall cause
their respective representatives on a Committee to use their reasonable efforts to resolve all matters presented to them as expeditiously as possible. In the event that the JPT is unable to make a decision due to a lack of required unanimity, either
Party may submit the dispute to the JSC, specifying the nature of the dispute with sufficient detail to permit adequate consideration. In the event that the JSC is unable to resolve a dispute or make a decision due to a lack of required unanimity
within [***] following consideration of the dispute or the decision by the JSC, then either Party may submit the matter to the Commercial Officers for a joint decision. The Commercial Officers shall diligently
and in good faith attempt to resolve the referred dispute expeditiously and, in any event, within [***] of receiving such written notification, or within such other time as mutually agreed upon in writing between such officers (and if the
officers resolve the dispute, such resolution shall be deemed to be a decision of the JSC). In the event that the Commercial Officers are unable to reach a resolution of the dispute within such time period, then: 

(i) if the dispute concerns any update or amendment to the Mallinckrodt Call List, the dispute shall be resolved pursuant to
Section 4.6, 
 (ii) if the dispute concerns (i) the [***], (ii) the [***] or (iii) material
changes to [***], the matter shall be determined by Zogenix after considering in good faith Mallinckrodt’s comments and positions with respect to the issue(s), and 

(iii) all other unresolved disputes shall be resolved pursuant to Section 15.1 below. 

For clarity, any dispute with respect to whether a Party has breached its obligations under this Agreement is not subject to the escalation procedures
set forth in this Section 3.5, but either Party may refer such a dispute for resolution pursuant to Section 15.1. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 15 

 ARTICLE IV 
 PRODUCT PROMOTION 
 Section 4.1 Product Detailing by
Mallinckrodt 
 (a) Subject to applicable Legal Requirements as well as the provisions of this Agreement, Mallinckrodt
shall, from and after the Promotion Commencement Date and during the Term, use commercially reasonable efforts to Detail the Product to Professionals on the Mallinckrodt Call List (the “Mallinckrodt Promotional Effort”),
provided, however, that (i) Mallinckrodt’s commercially reasonable efforts shall be deemed to be satisfied if Mallinckrodt materially complies with its obligations under Sections 4.1(b), 4.1(c), 4.1(d), 4.1(e) and 4.1(f) (such
obligations, the “Mallinckrodt Minimum Sales Effort”), and (ii) in the event that, [***]. Mallinckrodt shall cause the Mallinckrodt Sales Force and Mallinckrodt employees and agents acting on Mallinckrodt’s behalf
to comply with this Agreement and all applicable Legal Requirements in connection with the Detailing of the Product. Mallinckrodt will be accountable for the acts and omissions of the Mallinckrodt Sales Force and its employees and agents to the
extent such acts or omissions fail to comply with Mallinckrodt’s obligations under this Agreement. 

(b) Mallinckrodt shall commence Detailing the Product in accordance with this Agreement [***].

 (c) From the Promotion Commencement Date until
[***], Mallinckrodt shall Detail the Product to Professionals on the Mallinckrodt Call List [***]. 
 (d) [***].

 (e) During the first [***] following the Promotion Commencement Date, Mallinckrodt shall [***] related to the
[***]. 
 (f) Beginning with the [***] following the Promotion Commencement Date, Mallinckrodt shall purchase and
use commercially reasonable amounts of Promotional Materials and Samples to support its obligations under this Agreement. [***] related to [***] related to an [***] be [***] for the [***]. 

(g) Notwithstanding anything contained in this Section 4.1, Mallinckrodt shall have the right to [***], (ii) in the
event that Zogenix fails to maintain the continued effectiveness of the Regulatory Approval (the continued effectiveness of which shall be deemed not to have been maintained if the FDA or any other Governmental Authority suspends the manufacturing,
use, marketing, sale or promotion of the Product), (iii) in the event of a large-scale recall, market withdrawal, or similar corrective action with respect to the Product, or (iv) in the event that Zogenix or any of its Affiliates or, to
Zogenix’s knowledge, any Person under its or their direction or control, is debarred by the FDA under the Generic Drug Act. Once [***], Mallinckrodt’s obligations under this Section 4.1 shall be [***] if and [***]
on 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 16 

 
which (x) Zogenix is in compliance with the requirements of each of clauses (ii) through (iv), and (y) Zogenix has reasonably satisfied Mallinckrodt that Zogenix can continue to
satisfy such requirements on a going-forward basis (such date, the “[***]”), at which point Mallinckrodt shall use commercially reasonable efforts, taking account of the time reasonably required to rededicate the required level of
Mallinckrodt Promotional Effort (as defined in Section 4.1(a)) and other relevant circumstances related to the cause and effects of the [***], to [***] with the applicable requirements of this Section 4.1. For the avoidance
of doubt, the [***] Mallinckrodt from [***] pursuant to this paragraph shall be in addition to all other rights and remedies available to Mallinckrodt hereunder, at law or in equity or otherwise, with respect
to the event(s) triggering such release. 
 Section 4.2 Product Detailing by Zogenix

 Subject to applicable Legal Requirements as well as the provisions of this Agreement, Zogenix shall, from and after the
Promotion Commencement Date and during the Term use commercially reasonable efforts to Detail the Product within the Territory in accordance with the Commercial Plan. For clarity, Zogenix shall also have the right, but not the obligation, to Detail
the Product to Professionals on the Mallinckrodt Call List; provided that [***], regardless of any such Zogenix Promotional activity. Zogenix shall cause the Zogenix Sales Force and Zogenix employees and agents acting on Zogenix’s
behalf to comply with this Agreement and all applicable Legal Requirements in connection with the Promotion of the Product. Zogenix will be accountable for the acts and omissions of the Zogenix Sales Force and its employees and agents to the
extent such acts or omissions fail to comply with Zogenix’s obligations under this Agreement. 
 Section
4.3 Representations to Customers 
 Each Party shall, in connection with its Promotion of the Product, refrain from
making (i) any false or misleading representations to Professionals, customers or others regarding the other Party or the Product or (ii) representations, warranties or guarantees with respect to the specifications, features, or
capabilities of the Product that are not consistent with the Promotional Materials, the applicable then-current FDA approved labeling and package insert and applicable Legal Requirements. Each Party shall undertake timely corrective action with
respect to any deviations from this Section 4.3, subject to discussion and review by the other Party’s designated regulatory affairs and quality assurance personnel. 

Section 4.4 Staffing and Training 
 (a) Except as otherwise set forth in this Section 4.4, each Party shall be solely responsible for all costs and expenses incurred to train and compensate its Sales Representatives.

(b) Consistent with applicable Legal Requirements, and subject to Sections 4.1(c) and 4.1(d) , as applicable, [***]. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 17 

 (c) Zogenix and Mallinckrodt shall collaborate on the development and implementation of
sales training for the Mallinckrodt Sales Force. Zogenix shall make available a copy of its existing training materials as well as providing reasonably requested training assistance, which may be used by Mallinckrodt for initial and refresher
training of the members of the Mallinckrodt Sales Force. Such training materials and training assistance shall address the following matters: disease state, Product knowledge, competitive product knowledge, obligations under this Agreement,
coordination with counterparts on the Zogenix Sales Force, administration and other appropriate information. 
 (d) Subject to Section 5.3 and subject to Zogenix meeting the requirements of Section 4.4(c), Mallinckrodt shall provide training to each member of its Sales Force prior to his or her
commencement of Promotion of the Product hereunder to ensure that he or she is properly trained with respect to all matters described in Section 4.4(c) and able to satisfy his or her Promotion responsibilities under this Agreement, which shall
include no less than [***] and completion of [***] (the “Initial Sales Force Training Program”). Zogenix sales trainers shall participate in the Initial Sales Force Training Program as and to the
extent reasonably requested by Mallinckrodt and [***]. In addition to the Initial Sales Force Training Program, Mallinckrodt shall provide to the members of its Sales Force such reinforcement and refresher training with respect to the Product
consistent with such training provided by Zogenix to its Sales Force with the support and assistance of Zogenix, unless otherwise and to the extent mutually agreed. Specifically, if there are material changes in the Product labels and inserts
following the Promotion Commencement Date, Mallinckrodt shall provide training materials to each member of its Sales Force with respect to such matters provided Zogenix has made appropriate training materials available to Mallinckrodt.

 (e) Mallinckrodt shall only employ Sales Representatives to Promote the Product hereunder who demonstrate a competent
knowledge of the Product. 
 (f) [***], neither Party shall actively recruit or solicit for employment any then-current
member of the Sales Force of the other Party or any other staff member of the other Party who is engaged or had been engaged in the Promotion or Detailing of the Product. For the avoidance of doubt, nothing in this Agreement shall limit a Party from
engaging in general recruitment through advertisements or recruiting through “head-hunters” so long as the staff members of the other Party are not specifically targeted in such recruitment effort. 

Section 4.5 Promotional Materials; Speaker Events 

(a) It is the intent of the Parties that, in performing its Promotion obligations hereunder, Mallinckrodt will utilize promotional,
advertising, marketing, educational and training materials that have been produced by Zogenix with respect to the Product (“Promotional Materials”). All such materials, whether printed or electronic (including content on the
Product Website), shall be deemed Promotional Materials. Promotional Materials may include, by way of example: detailing aids, leave behind educational items, journal advertising, educational programs, formulary binders, appropriate reprints and
reprint carriers, product monographs, patient support kits, convention exhibit materials, direct mail, training materials, and scripts for telemarketing and teleconferences.

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 18 

 (b) All Promotional Materials to be used by Mallinckrodt shall be reviewed and approved by
Zogenix’s promotional review committee prior to their use by Mallinckrodt. Zogenix shall provide to Mallinckrodt on a timely basis (i) fully referenced copies of Promotional Materials approved by Zogenix and, (ii) if necessary for
review, a prototype of any Promotional Materials approved by Zogenix, in each case ((i) and (ii)), for internal review by Mallinckrodt. Mallinckrodt shall have the right to review any Promotional Materials and Mallinckrodt shall not be required to
use any Promotional Materials that are not reviewed by and acceptable to Mallinckrodt’s promotional review committee. If, after its review of any Promotional Materials (including any new materials introduced after the Effective Date or the
Promotion Commencement Date), Mallinckrodt believes that changes to any such Promotional Materials are required to meet Legal Requirements or applicable FDA or other regulatory requirements, such proposed changes shall be advanced for determination
in accordance with procedures to be established by the Parties. 
 (c) The Parties shall, through their
representatives on the JPT, use commercially reasonably efforts to ensure sufficient quantities of Promotional Materials are made available for use in Promoting the Product and performing their respective obligations hereunder. Zogenix shall provide
to Mallinckrodt such quantities of Promotional Materials as reasonably requested by Mallinckrodt in writing and with delivery dates to be mutually agreed between the Parties on a request by request basis; Mallinckrodt shall pay Zogenix for any
Promotional Materials delivered to Mallinckrodt pursuant to its written request, within [***]. Mallinckrodt shall be permitted to use in connection with the Promotion of the Product only (i) the Promotional Materials approved
under this Agreement by each of Zogenix and Mallinckrodt and (ii) the FDA-approved Product labels and inserts. Mallinckrodt shall use such Promotional Materials only in the form so approved and consistent with the training provided pursuant to
Section 4.4 and Mallinckrodt shall not change such Promotional Materials in any way following such approval and training, without the express written consent of Zogenix. 

(d) All Promotional Materials shall comply with all applicable Legal Requirements. Notwithstanding anything in this Agreement to the
contrary, neither Party shall be required to take any action if such Party reasonably determines that such action would violate applicable Legal Requirements, including any such action involving the use or dissemination of any Promotional Materials
or training materials. 
 (e) The Parties shall at all times during the Term collaborate, through their representatives on the
JPT, in determining [***], including [***]. In [***] a [***], Mallinckrodt shall [***] only [***] which are on [***] and shall use only materials previously approved by Zogenix and the promotional
review committee of Mallinckrodt. 
 (f) Subject to this Section 4.5(f), Zogenix shall own all copyrights to all
Promotional Materials that are created during the Term (other than those items which are 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 19 

 
subject to Third Party copyrights). Zogenix shall, and does hereby, grant to Mallinckrodt a royalty-free, non-exclusive right and license to use, reproduce and distribute Promotional Materials or
any other Product-related materials made available to Mallinckrodt by Zogenix hereunder, in each case solely in conjunction with the Promotion of the Product and the performance of Mallinckrodt’s obligations under this Agreement, which license
shall not be sublicensable, assignable or transferable by Mallinckrodt, except in accordance with the terms of Section 2.2. 
 Section 4.6 Mallinckrodt Call List 
 The
Mallinckrodt Call List may be mutually updated to add Professionals that are not then on the Zogenix Call List [***], in all cases [***] in [***]. For purposes of aiding the Parties in
determining which Professionals may be added to the Mallinckrodt Call List, Zogenix shall provide an updated Zogenix Call List to Mallinckrodt periodically on a timely basis. Each proposed update to the Mallinckrodt Call List shall be prepared by
the JPT and submitted to the JSC for review and discussion. The JSC shall use all reasonable efforts to review and provide comments to any update to the Mallinckrodt Call List as expeditiously as possible. In the event the JSC is unable, and,
failing agreement by the JSC, the Commercial Heads are unable, to agree on any such update to the Mallinckrodt Call List, the last-approved Mallinckrodt Call List shall remain in effect. If Mallinckrodt makes a request for inclusion of new potential
Professionals who are not set forth on the Zogenix Call List and who constitute [***] of the number of Professionals on the then-current Mallinckrodt Call List, and the JSC does not allow the new potential Professionals to be included,
[***]. 
 Section 4.7 Promotion Reports 

Within [***] following the end of each [***], Mallinckrodt shall provide the JSC with a status report, which report will
summarize Mallinckrodt’s [***] pursuant to this Agreement for such prior [***] and [***], including: [***]. 
 Section 4.8 Medical Inquiries 
 Zogenix shall be solely responsible
for all medical affairs activities relating to the Product, including medical information support and medical communications and publishing activities, which activities shall be performed by or on behalf of Zogenix at its sole expense. The Parties
acknowledge that each Party may receive requests for medical information concerning the Product from members of the medical and paramedical professions and consumers. Zogenix shall have the exclusive right to respond to questions and requests for
information about the Product received from such Persons that (i) warrant a response beyond the understanding of the Sales Representative or (ii) are beyond the scope of the Product labels and inserts (each such request, a
“PIR”). If PIRs are received by Mallinckrodt, the requests will be referred to Zogenix’s medical information department or any appointed Third Party vendor to which Zogenix has instructed Mallinckrodt in writing to refer PIRs.
Zogenix shall also be responsible for responding to PIRs that are not received by Mallinckrodt. Zogenix’s responses to PIRs and its performance of its obligations under this Section 4.8 shall be in compliance with all applicable Legal
Requirements and the NDA. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 20 

 Section 4.9 Trademarks 

(a) The “Zogenix” Trademark must appear on all Promotional Materials that make reference to the Product, to the extent such
Promotional Materials would typically contain a company trademark. The “DosePro” Trademarks must appear on all Promotional Materials that make reference to the “DosePro” delivery device incorporated into the Product and the
“Sumavel” and “DosePro” Trademarks (or such other FDA-approved Trademarks) must appear on all Promotional Materials that make reference to the Product (or such Trademark). In no event shall Zogenix use or permit or cause to be
used in connection with the Product or the Promotion thereof any Trademark other than a Zogenix Trademark, and in the case of any Mallinckrodt Trademark, only any such Mallinckrodt Trademark which is the subject of a Trademark Consent. Zogenix
hereby grants to Mallinckrodt a non-exclusive, royalty-free right and license to use the Zogenix Trademarks in the Territory solely in connection with the Promotion of the Product and Mallinckrodt’s performance of its obligations under the
Agreement, which license shall not be sublicensable, assignable or transferable except to any Third Party providing Sales Representatives for or acting as the Mallinckrodt Sales Force or in accordance
with the terms of Section 2.2. Such license shall expire immediately upon the expiration or termination of this Agreement. Mallinckrodt recognizes
Zogenix’s title to the Zogenix Trademarks, and shall not at any time intentionally take or knowingly allow any act or thing which would impair the rights of Zogenix in or to the Zogenix Trademarks. Mallinckrodt acknowledges and agrees that it
shall not acquire and shall not claim any title to the Zogenix Trademarks by virtue of the rights granted under this Agreement or through Mallinckrodt’s use of the Zogenix Trademarks hereunder, and that all goodwill generated by Mallinckrodt in
connection with the use of the Zogenix Trademarks shall inure to the benefit of Zogenix. 
 (b) Mallinckrodt hereby grants to
Zogenix a non-assignable, non-sublicensable (except to any Third Party providing Sales Representatives for or acting as the Zogenix Sales Force), non-exclusive, royalty-free right and license to use those Mallinckrodt Trademarks in the Territory
that are approved in advance in writing by an authorized officer of Mallinckrodt, solely for any specific use related to the Promotion of the Product in the Territory that is approved in such writing (any such approval, a “Trademark
Consent”). Such license shall expire immediately upon the expiration or termination of this Agreement. Zogenix recognizes Mallinckrodt’s title to the Mallinckrodt Trademarks, and shall not at any time intentionally take or
knowingly allow any act or thing which would impair the rights of Mallinckrodt in or to the Mallinckrodt Trademarks. Zogenix shall not have any right or license to use (and shall not use) any Mallinckrodt Trademarks in connection with the
Promotion of the Product or otherwise unless and until a Trademark Consent is obtained for the specific use. Zogenix acknowledges and agrees that it shall not acquire and shall not claim any title to the Mallinckrodt Trademarks by virtue of the
rights granted under this Agreement or through Zogenix’s use of the Mallinckrodt Trademarks hereunder, and that all goodwill generated by Zogenix in connection with the use of the Mallinckrodt Trademarks shall inure to the benefit of
Mallinckrodt. 
 (c) Each of Mallinckrodt, with respect to its use of the Zogenix Trademarks, and Zogenix, with respect to its
use of the Mallinckrodt Trademarks, will maintain 

  
 21 

 
quality standards for all of its uses of the Trademarks of the other Party in connection with the Promotion of the Product that are substantially equivalent to those standards that are
(i) used by the owner of such Trademarks in connection with pharmaceutical products, and (ii) communicated by the owner to the other Party in writing and (iii) commercially reasonable.

Section 4.10 Product Website 

Zogenix shall maintain a Product website designed with respect to the Promotion of the Product in the Territory (the
“Product Website”) and shall implement any changes to the Product Website in accordance with any relevant procedures set forth in Section 4.5 with respect to Promotional Materials. Expenses associated with maintaining and
updating the Product Website shall be [***]. Zogenix shall ensure that the Product Website complies with all applicable Legal Requirements. 
 ARTICLE V 
 CLINICAL, COMPLIANCE, AND REGULATORY AFFAIRS 

Section 5.1 Regulatory Approvals 
 Zogenix shall use diligent efforts to maintain and continue all Regulatory Approvals for the Product. Mallinckrodt agrees that all Regulatory Approvals, applications therefor and any other submissions to
a Governmental Authority with respect to the Product shall be in the name of, and shall be owned by, Zogenix or its designee. During the Term, Zogenix shall provide Mallinckrodt with access, free of charge, to all clinical and non-clinical data
related to the Product generated by or on behalf of and owned or otherwise Controlled by Zogenix, whether before or after the Effective Date. 
 Section 5.2 Compliance with Regulatory Requirements 
 Unless
otherwise required by applicable Legal Requirements or expressly provided by this Agreement, Zogenix will retain exclusive authority over and responsibility for complying with all regulatory requirements and maintaining all contacts with
Governmental Authorities with respect to the Product, including the maintenance and updating of the NDA, the development and submission of applications for new formulations, dosage strengths or indications of the Product, the reporting of any
Adverse Drug Experiences to the FDA, the compliance of Promotional Materials with FDA rules and regulations, and the filing of Promotional Materials with the FDA. 

Section 5.3 Compliance 
 (a) During the Term, Mallinckrodt, its Affiliates, and its and their employees, agents, representatives, and contractors having any interactions with Health Care Providers with respect to the Product
shall comply with applicable Legal Requirements [***]. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 22 

 (b) During the Term, Zogenix, its Affiliates, and its and their employees, agents,
representatives, and contractors having any interactions with Health Care Providers with respect to the Product shall comply with applicable Legal Requirements and [***]. 

(c) In performing its duties hereunder, each Party shall, and shall cause the Mallinckrodt Sales Force or Zogenix Sales Force, as
applicable, its Affiliates, and its and their employees, agents, representatives, and contractors to comply with applicable Legal Requirements. Each Party shall ensure that none of it, its Sales Force, its Affiliates, and its and their employees,
agents, representatives and contractors shall offer, pay, solicit or receive any remuneration to or from any Professional in order to induce referrals of or purchase of the Product in violation of applicable Legal Requirements, including
anti-kickback Legal Requirements. Mallinckrodt shall train the Mallinckrodt Sales Force and Zogenix shall train the Zogenix Sales Force, each in compliance with applicable Legal Requirements, prior to engaging in Promotion of the Product.

 (d) Notwithstanding any other term or condition of this Agreement, neither Party shall be required to participate in, fund,
or support any sales or marketing activities that in such Party’s judgment would conflict with or be inconsistent with such Party’s Compliance Materials or any applicable Legal Requirements. 

Section 5.4 Communications with Regulatory Authorities 

(a) Except to the extent set forth in Section 5.4(b), all communications with Government Authorities concerning
the Product shall be the sole responsibility of Zogenix. Zogenix shall, [***] after being sent or received, provide Mallinckrodt with copies of all material communications related to Promotional Materials and Serious
Adverse Drug Experiences and shall reasonably and promptly respond to all inquiries by Mallinckrodt relating thereto. Zogenix shall periodically provide Mallinckrodt with a summary of all other communications related to Promotional Materials and
Serious Adverse Drug Experiences received, directly or indirectly, by Zogenix, but in no event [***]. 
 (b)
Mallinckrodt shall not, without the consent of Zogenix, correspond or communicate with the FDA or with any other Governmental Authority, whether within the Territory or otherwise, concerning the Product, or otherwise take any action concerning any
Regulatory Approval under which the Product is sold or any application for Regulatory Approval of the Product; provided that Mallinckrodt shall have the right to do so: (i) if Mallinckrodt believes in good faith that it is necessary to
do so to comply with the terms of this Agreement or any Legal Requirement (including state or local Legal Requirements related to Promotional activities undertaken by Mallinckrodt or the Mallinckrodt Sales Force), or (ii) at the request of a
Governmental Authority (provided that, where practicable, Mallinckrodt shall have requested that such Governmental Authority communicate with Zogenix instead), and in each such case, ((i) or (ii)), to the extent permitted by Legal Requirements and
not prohibited by the Governmental Authority, Mallinckrodt shall give Zogenix notice as soon as reasonably 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 23 

 
practicable of such communication and, to the extent practicable, shall permit Zogenix to accompany Mallinckrodt, take part in any such communications and receive copies of all such
communications. Mallinckrodt shall [***] after receipt of any communication from the FDA or from any other Governmental Authority relating to the Product, to the extent so permitted by Legal Requirements and not so prohibited by the FDA
or the applicable Governmental Authority, forward a copy of the same to Zogenix and reasonably respond to all inquiries by Zogenix relating thereto. If Mallinckrodt is required by Legal Requirements to communicate with the FDA or with any other
Governmental Authority relating to the Product or is requested to do so by the FDA or the Governmental Authority, then Mallinckrodt shall so advise Zogenix, to the extent practicable and permitted by Legal Requirements and not prohibited by the FDA
or the Governmental Authority, within [***] and shall provide Zogenix in advance with a copy of any proposed written communication, or a written summary of any proposed oral communication with the FDA or any other Governmental Authority.
Mallinckrodt shall comply with any and all reasonable direction of Zogenix concerning any meeting or written or oral communication with the FDA or any other Governmental Authority relating to the Product unless otherwise required by Legal
Requirements or otherwise requested by the FDA or the other Governmental Authority. 
 Section 5.5 Product
Complaints 
 Mallinckrodt shall refer any oral or written Product Complaints which it receives
concerning the Product to Zogenix within [***] of its receipt thereof; provided, that all Product Complaints concerning suspected or actual Product tampering, contamination or mix-up shall be delivered within [***] its
receipt thereof. Mallinckrodt shall not take any other action in respect of any such Product Complaint without the consent of Zogenix unless otherwise required by applicable Legal Requirements. At Zogenix’s request, Mallinckrodt will
reasonably cooperate with Zogenix to resolve any Product Complaints [***]. All Product Complaints shall be directed to the attention of Zogenix’s Vice President, Regulatory Affairs, at Zogenix’s address set forth in
Section 13.1 (or to Zogenix’s designated Third Party vendor providing such services to Zogenix, at Zogenix’s request). Zogenix shall regularly provide Mallinckrodt with a summary of all Product Complaints received, directly or
indirectly, by Zogenix as reasonably requested by Mallinckrodt, but in no event [***]; provided, however, that Zogenix shall provide Mallinckrodt with all Product Complaints concerning suspected or actual Product tampering,
contamination or mix-up within [***] of its receipt thereof. 
 Section 5.6 Adverse Drug
Experience Reports 
 (a) Mallinckrodt shall notify Zogenix: (i) of all Serious Adverse Drug Experience
Reports within [***] of the time such Serious Adverse Drug Experience Report becomes known to Mallinckrodt and (ii) of all Adverse Drug Experience Reports within [***] of the time such Adverse Drug Experience Report becomes known
to Mallinckrodt. 
 (b) Except as may otherwise be required by Legal Requirements, (i) Mallinckrodt shall not disclose any
information concerning Adverse Drug Experience Reports or Serious Adverse Drug Experience Reports to any Person or Governmental Authority without 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 24 

 
the prior written consent of Zogenix and (ii) Zogenix shall have the sole discretion to determine whether any Product Complaint, Adverse Drug Experience Report or Serious Adverse Drug
Experience Report must be reported to the FDA or any other Governmental Authority. 
 (c) All follow-up investigations
concerning Adverse Drug Experience Reports and Serious Adverse Drug Experience Reports shall be conducted by Zogenix or its appointed Third Party vendor to which Zogenix has delegated such authority. At Zogenix’s request, Mallinckrodt
shall provide all reasonable cooperation with any such follow-up investigation. Zogenix shall reimburse Mallinckrodt for its reasonable, out-of-pocket expenses for such cooperation. 

(d) Within [***] days of the Effective Date, the Parties will enter into a
separate and more detailed pharmacovigilance agreement, consistent with the terms of this Agreement; but in the event of any conflict or inconsistency between the terms of such new agreement and this Agreement, the latter shall prevail in every
case. Zogenix shall maintain, at its sole expense, the global safety database relating to the Product, and shall be responsible for complying with all reporting and other applicable Legal Requirements related thereto. 

Section 5.7 Recalls or Other Corrective Action 

Zogenix shall have sole responsibility for and shall make all decisions with respect to any recall (including recall of packaging and
Promotional Materials), market withdrawals, or any other corrective action related to the Product. Zogenix shall [***] with respect to any such actions proposed to be taken by Zogenix in the Territory (and in all events reasonably in
advance of the taking of such actions), including [***]. At Zogenix’s request, Mallinckrodt shall provide reasonable assistance to Zogenix in conducting such recall, market withdrawal, or other corrective action (including
retrieving Samples distributed by the Mallinckrodt Sales Force to Professionals). [***]. 
 Section
5.8 Assistance 
 Each Party agrees to provide to the other Party all reasonable assistance, and to take all
actions reasonably requested by the other Party, in each case that are reasonably necessary to enable the other Party to comply with any Legal Requirement applicable to the Product in the Territory. Except as otherwise expressly provided herein
[***], except to the extent [***]. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 25 

 ARTICLE VI 
 MANUFACTURING AND SUPPLY; SALES; PRICING 
 Section 6.1
Obligations of Zogenix 
 (a) In accordance with the provisions of this Agreement and all applicable Legal
Requirements, Zogenix shall, at its cost and expense, use commercially reasonable efforts to perform or cause to be performed all Product manufacture, labeling, packaging, warehousing, distribution and return, order entry, payment processing,
customer services and all other activities to supply and distribute the Product in the Territory. 
 (b)
Zogenix shall use commercially reasonable efforts to ensure Timely Supply [***]. In addition, Zogenix shall use commercially reasonable efforts to maintain during each [***] the appropriate amount of Safety Stock
for such [***]. 
 Section 6.2 Mallinckrodt Forecasts; Sample Forecasts 

(a) Prior to the Promotion Commencement Date, Mallinckrodt will provide to Zogenix a written non-binding forecast, [***], of the
expected Mallinckrodt Call List Dispensed Units during the [***] period beginning with the Promotion Commencement Date, which forecast will be prepared by Mallinckrodt in good faith. At least [***] prior to the beginning of each
[***] (beginning with the first [***] after the Promotion Commencement Date), Mallinckrodt shall prepare and provide to Zogenix a written non-binding forecast, [***], of the expected Mallinckrodt Call List Dispensed Units during
the [***] period beginning with such [***], which forecast shall be prepared by Mallinckrodt in good faith. 

(b) At least [***] prior to the beginning of each [***], Mallinckrodt shall prepare and provide to Zogenix a written
non-binding forecast [***] of the expected Mallinckrodt Sample requirements during the [***] period beginning with such [***], which forecast shall be prepared by Mallinckrodt in good faith and consistent with
Mallinckrodt’s obligations pursuant to Sections 4.1(f) and 6.5(b) (the “Sample Forecast”). 
 (c) In the
event that in any [***], Zogenix and its Affiliates have insufficient inventory of Product to satisfy Trade Demand, then the Parties shall work in good faith to address such shortfall, including by allowing Safety Stock to temporarily fall
below the level required by Section 6.1(b), reallocating Sample production to trade and other such measures as the Parties may agree. 
 Section 6.3 [***] 
 (a) [***], Zogenix shall provide to Mallinckrodt
[***]. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 26 

 (b) Zogenix shall promptly (and in no event later than [***] inform Mallinckrodt of
[***]. 
 (c) If reasonably requested by either Party, Mallinckrodt and Zogenix shall [***],
and [***] to [***]. 
 Section 6.4 Sales; Pricing 

Zogenix or its Affiliates shall book all sales of the Product in the Territory and shall be responsible for entering into any contracts and other
arrangements with any Person regarding the sale of the Product. Zogenix shall be responsible for establishing and approving the form, content, and terms and conditions of contracts and other arrangements, including any discount, allowance, rebate,
chargeback, or other term granted therein. Zogenix shall use commercially reasonable efforts to obtain favorable terms under such contracts. 
 Section 6.5 Samples 
 (a) Zogenix shall use commercially reasonable
efforts to provide or cause to be provided to Mallinckrodt, as ordered by Mallinckrodt hereunder, samples of the Product that are not for sale and are distributed with no fee associated and are delivered with [***]
(“Samples”) to be distributed by Mallinckrodt solely in connection with the performance of Details to Professionals in accordance with this Agreement. 
 (b) As of the Effective Date, Mallinckrodt has [***] for [***] for delivery during [***]. [***], during [***], Mallinckrodt [***]. 

(c) Mallinckrodt shall place all Sample Orders, [***], at least [***] in advance of the [***] set forth in such
Sample Orders, consistent with its obligations pursuant to Sections 4.1(f) and 6.5(b); provided that if the Sample Orders require [***] more than [***] of the most recent non-binding Sample Forecast during any [***] period,
Zogenix shall not be required to deliver such [***] Samples sooner than [***] after receipt of the applicable Sample Order. If requested by Mallinckrodt, subject to the immediately preceding sentence, Zogenix shall use commercially
reasonable efforts to deliver Samples prior to the delivery date set forth in the Sample Order. [***] after a Sample Order is received by Zogenix, Zogenix shall be deemed to have accepted such Sample Order provided that such Sample Order
complies with the ordering requirements of this Section 6.5. 
 (d) Zogenix shall deliver all Samples ordered by
Mallinckrodt in accordance with Section 6.5(c) to Mallinckrodt [***] by the [***] specified in each Sample Order, and [***]. Zogenix shall invoice Mallinckrodt for each shipment of Samples, at the time of shipment,
[***].
 (e) Samples supplied by Zogenix to Mallinckrodt shall be used by Mallinckrodt solely in performing Details to
Professionals in accordance with this Agreement.

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 27 

 
Upon its receipt of Samples, Mallinckrodt shall be solely responsible for accountability and compliance with the PDMA for the Mallinckrodt Sales Force, and other applicable Legal Requirements
relating to the distribution of such Samples by the Mallinckrodt Sales Force, and shall be responsible for adherence by its Sales Representatives to such Legal Requirements. Mallinckrodt shall also be responsible for securing the return and
appropriate disposal of and reconciling existing Sample inventories from discontinued Mallinckrodt Sales Representatives and upon the termination or expiration hereof. 

Section 6.6 Manufacturing Matters 
 (a) Zogenix shall promptly inform Mallinckrodt in the event that Zogenix becomes aware of any manufacturing matters which might reasonably be expected to (i) [***], (ii) have an
[***], or (iii) otherwise prevent or delay Mallinckrodt in [***]. 
 (b) Notwithstanding the generality of
the foregoing, Zogenix agrees to notify Mallinckrodt within [***] after Zogenix has become aware of any event or circumstance related to the manufacture of the Product that would [***] that has been released by Zogenix or that would
[***]. 
 ARTICLE VII 
 COMPENSATION; RECORDKEEPING; AUDITS 
 Section 7.1
Service Fees and Adjustment Payments 
 (a) In partial consideration for Mallinckrodt’s
performance of its obligations under this Agreement, Zogenix shall pay to Mallinckrodt (i) a service fee (the “Service Fee”) equal to (A) [***] of Mallinckrodt Net Sales for each [***] during
[***], and (B) [***] of Mallinckrodt Net Sales for each [***] thereafter, and (ii) any [***] payment required under Section 7.1(d). [***]. 

(b) Within [***] following the end of each [***], Zogenix shall provide Mallinckrodt with a statement in a mutually
agreeable format setting forth: [***], subject to later adjustment pursuant to Section 7.1(d) below. 
 (c) The
Service Fee will be paid to Mallinckrodt within [***] after the end of the [***] and will not be subject to an offset for any payments that may be due hereunder by Mallinckrodt to Zogenix unless the Parties agree otherwise. 

(d) No earlier than the [***] following the [***] (or as otherwise agreed by the Parties), Zogenix shall [***]. Such
[***]. If Zogenix is required to make a payment to Mallinckrodt to effect such [***], then Zogenix shall provide such payment to Mallinckrodt along with such [***]. If Mallinckrodt is required to make a payment to Zogenix to
effect such [***], Mallinckrodt shall make such payment directly to Zogenix within [***] following receipt of the [***]). Zogenix shall provide to Mallinckrodt, along with the [***], all documentation reasonably necessary
to explain or support the [***] (as well as such other information as Mallinckrodt shall reasonably request), in a form to be agreed by the Parties. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 28 

 (e) If either of the Parties believes that the [***]. The
Parties shall discuss in good faith any [***] that are [***]. 
 Section 7.2 Tail Payment 
 Following the Term, except as set forth in
Section 8.4(a), Zogenix shall pay Mallinckrodt an amount equal to [***] of the Mallinckrodt Net Sales [***], which calculation shall be made using the [***] Mallinckrodt Call List and the Net Selling Price for the [***]
(such period, the “Tail Period”, such payment, a “Tail Payment”). The Tail Payment will be paid to Mallinckrodt within [***] after the end of the Tail Period, and will not be subject to [***],
unless the Parties agree otherwise. 
 Section 7.3 Maintenance of Records; Audits 

(a) Consistent with the requirements of Section 7.3(b) below, each Party shall maintain the following books and records to the
extent created consistent with its ordinary and reasonable compliance, operating and accounting procedures, as applicable in any given case: 
 (i) books and records documenting the Party’s compliance with applicable Legal Requirements and the applicable requirements of Articles IV, V and VI (“Compliance Records”); such
Compliance Records shall include the Party’s policies and procedures concerning compliance with applicable Legal Requirements and the requirements of Articles IV, V, and VI then in effect, and records of any investigations and remedial and
disciplinary actions taken to address material violations of applicable Legal Requirements or the requirements of Articles IV, V, or VI, 
 (ii) in the case of Mallinckrodt, books and records documenting Mallinckrodt’s performance of its Promotional efforts hereunder, including books and records documenting (A) the number of
individual Sales Representatives Promoting the Product in [***], (B) all Vacancies in the Sales Force Promoting the Product, (C) [***], and (D) [***] with respect to the periods in which these metrics are
applicable (“Promotion Records”), 
 (iii) in the case of Mallinckrodt, books and records documenting
Mallinckrodt’s performance of its training obligations hereunder (“Training Records”), 
 (iv) in the
case of Mallinckrodt, books and records documenting Expenses (“Expense Records”), 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 29 

 (v) in the case of Zogenix, books and records documenting all Sample Orders, Trade Demand,
Safety Stock, Sample Orders fulfilled, Product distributed by Zogenix in the Territory, and in the case of Mallinckrodt, books and records documenting all Samples distributed by Mallinckrodt in the Territory (with respect to a Party, its
“Volume Records”), 
 (vi) in the case of Zogenix, books and records documenting gross invoiced sales of
Product in the Territory, Deductions, Mallinckrodt Call List Dispensed Units, and Territory Invoiced Units during each [***], and any related adjustments and reconciliations for [***], as well as all documents reflecting Zogenix’s
[***] for any items sold or charged by Zogenix to Mallinckrodt hereunder (“Net Sales and Financial Records”), and 
 (vii) any other books and records of either Party that are reasonably related to performance hereunder and that might be necessary for the determination of whether or not either or both Parties have
satisfied their obligations hereunder. 
 (b) Such books and records shall be maintained for the greater of
[***] to which such books and records pertain, and such additional period as is required by applicable Legal Requirements. Such books and records shall be complete and accurate, and maintained, when
applicable, in accordance with such Party’s accounting practices, consistently applied. Such books and records shall be maintained in sufficient detail and only for the purpose of enabling a Third Party to verify, in any given circumstance,
that a Party has met its obligations hereunder or acted in compliance with the requirements hereof. 
 (c) Upon
[***], such books and records shall be made available for audit during business hours by an independent certified public accounting firm or other appropriate Third Party expert designated by the other Party and reasonably acceptable to the
Party being audited for the purposes set forth in Section 7.3(b). Each Party shall cooperate with the audit. A Party may exercise this audit right no more frequently than [***] and no later than [***] following the applicable
period of time. The results of any audit shall be shared by the auditing Party with the audited Party. 
 (d) If the audit
concludes that additional payments were owed or that excess payments were made during such period, the owing Party shall pay the additional payments or the receiving Party shall reimburse such excess payments within [***], and such payments
will [***] by one Party to the other Party. 
 (e) The fees and expenses of the auditor shall be borne by the auditing
Party; provided, however, that if the audit reveals that the audited Party (i) is or was not in material compliance with Legal Requirements or the requirements of Articles IV, V, or VI or its obligations hereunder, or (ii) has
reported or calculated incorrectly expenditures, payments, Expenses, Net Sales figures, Mallinckrodt Net Sales figures, Territory Invoiced Unit figures or Mallinckrodt Call List Dispensed Unit figures, Direct Costs or the adjustments or
reconciliations contemplated in Section 7.1, and the amount of such discrepancy resulted in an underpayment of 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 30 

 
at least [***] of the aggregate amount that should have been paid for the period examined with respect to all such adjustments, taking into account any adjustments or reconciliations under
Section 7.1, then in either case ((i) or (ii)) the audited Party shall pay the entire amount of the audit fees and expenses. 
 (f) If the audited Party disputes the audit, such Party promptly shall notify the other Party in writing and the Parties shall use good faith efforts to resolve such dispute. If the Parties are unable to
resolve such dispute within [***], an independent accounting firm mutually agreed to by the Parties (the costs of which shall be paid one-half by each Party) shall resolve such dispute and such accounting firm’s resolution shall be final
and binding on the Parties. Each Party shall cooperate with such accounting firm’s investigation. 

Section 7.4 Payments 

Any payments required to be made under this Agreement shall be made in United States dollars via wire transfer of
immediately available funds to such bank account as a Party shall designate in writing prior to the date of such payment. All payments shall bear interest from the date due until paid (including any adjustments made as a consequence of audit in
accordance with Section 7.3 above, but it is understood that any adjustments made as a consequence of Section 7.3 shall not be deemed amounts due until payable in accordance with the specific payment requirements of Section 7.3(d)) at
a rate equal to the [***], as quoted by the Wall
Street Journal, New York Edition, on the date such payment was due, or, if less, the maximum rate permitted by applicable law. 

ARTICLE VIII 
 TERM AND TERMINATION 
 Section 8.1 Term

 The term of this Agreement shall commence on the Effective Date and shall continue, unless terminated sooner in accordance with this Article
VIII, until June 30, 2014 (the “Initial Term”). The Initial Term shall be extended automatically for additional successive six (6) month periods, absent ninety (90) days prior written notice from either Party to the
other Party that it does not want the Initial Term so extended automatically (the Initial Term, as may be extended, the “Term”). 
 Section 8.2 Early Termination 
 (a) Mallinckrodt Termination
Rights. 
 (i) Mallinckrodt may terminate this Agreement with sixty (60) days prior written notice to Zogenix in the
event that: 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 31 

 (A) Zogenix makes (i) any changes to [***] to take effect during the Term,
(ii) [***] or (iii) [***], and 
 (B) such changes are not approved by the JSC, and 

(C) such changes (x) result in an [***] as compared to the previously applicable [***] and (y) in
Mallinckrodt’s reasonable judgment would have [***]. 
 For clarity, [***], including [***] due to
[***], shall not give rise to a Mallinckrodt
termination right under this Section 8.2(a)(i). 
 (ii) Mallinckrodt may terminate this Agreement by providing ninety
(90) days’ prior written notice to Zogenix pursuant to the last sentence of Section 4.6. 
 (iii) Mallinckrodt
may terminate this Agreement immediately upon written notice to Zogenix in any of the following circumstances: (A) any Governmental Authority takes any action or raises any objection that prevents Mallinckrodt from performing its obligations
under this Agreement or makes or would reasonably be expected to make such activity unlawful or would reasonably be expected to subject Mallinckrodt to any penalty or any claim, investigation or similar action, in each case by such Governmental
Authority, (B) a Zogenix Supply Failure occurs or (C) a Third Party files an action alleging in writing that the using, making, having made, selling, offering for sale or importing of the Product infringes an issued patent in the Territory
controlled by such Third Party. 
 (b) Zogenix Termination Rights. Zogenix may terminate this Agreement with sixty
(60) days’ prior written notice to Mallinckrodt if Mallinckrodt breaches its Mallinckrodt Minimum Sales Effort obligation (and such breach must be described with reasonable specificity in such notice); provided that with respect to
the first such breach with respect to which Zogenix has provided notice to Mallinckrodt pursuant to this Section 8.2(b) in any twelve (12) month period, such termination shall not become effective if Mallinckrodt cures the breach within
such sixty (60) day notice period. For the avoidance of doubt, with respect to the second or any subsequent breach within any twelve (12) month period with respect to which Zogenix has provided notice to Mallinckrodt pursuant to this
Section 8.2(b), the termination shall become effective at the end of such sixty (60) day notice period if, notwithstanding any cure by Mallinckrodt, Zogenix fails expressly to accept any such cure. 

(c) Mutual Termination Rights. 
 (i) Either Party shall have the right to terminate this Agreement immediately upon written notice to the other Party in the event of a large-scale recall or withdrawal of the Product from the Territory
resulting from a significant safety risk inherent in the Product and not due to tampering, a remediable manufacturing problem, or other defect that can be cured with respect to the Product manufactured after such risk is discovered. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 32 

 (ii) Either Party shall have the right to terminate this Agreement upon thirty
(30) days’ prior written notice to the other Party if Mallinckrodt Net Sales fall below the Minimum Net Sales Threshold in any [***] beginning with the [***] ending December 31, 2012. Such notice shall be given within
thirty (30) days after the first date on which the Mallinckrodt Net Sales data for the relevant period are provided to Mallinckrodt by Zogenix pursuant to Section 7.1(b). The “Minimum Net Sales Threshold” means an amount
equal to [***]. 
 (iii) Either Party shall have the right to terminate this Agreement by providing ninety
(90) days’ prior written notice to the other Party in the event of a Change of Control of either Party, which notice must be delivered to the other Party within thirty (30) days after the closing of the transaction constituting a
Change of Control or neither Party shall have the right to terminate this Agreement as a result of the occurrence of such Change of Control. 
 (iv) Either Party shall have the right to terminate this Agreement upon thirty (30) days’ prior written notice to the other Party if a Third Party enters the Territory with a Generic Product.

 (v) Except with respect to events giving rise to early termination elsewhere in this Section 8.2, either Party may
terminate this Agreement with sixty (60) days’ prior written notice to the other Party in the event of a material failure of the other Party to comply with its material obligations contained in this Agreement (and such failure must be
described with reasonable specificity in such notice); provided that such termination shall not become effective if the breaching Party cures such failure within such sixty (60) day period. Notwithstanding the previous sentence, in the
case of a material failure of Zogenix to comply with its Safety Stock obligations under Section 6.1(b), Mallinckrodt shall have the right to terminate this Agreement upon ninety (90) days’ prior written notice, and such termination
shall not become effective with respect to the first such material failure with respect to such Safety Stock obligations in any twelve (12) month period if Zogenix cures the material failure within such ninety (90) day period. For the
avoidance of doubt, with respect to the second or any subsequent material failure with respect to such Safety Stock obligations within any twelve (12) month period with respect to which Mallinckrodt has provided notice to Zogenix pursuant to
this Section 8.2(c)(v), the termination shall become effective at the end of such ninety (90) day period, notwithstanding any cure by Zogenix. 
 (vi) In the event that, during the first full [***] after the expiration of [***] from and after the Promotion Commencement Date, the [***] for the Product in the Territory (as determined from the Third Party Audit) is not equal to or greater than
[***], at any time through the end of the [***] after the expiration of [***] from and after the Promotion Commencement Date, either Party shall have the right to terminate this Agreement effective upon ninety (90) days
written notice to the other Party unless, within the first sixty (60) days of such notice period, the Parties are able to renegotiate this Agreement and enter into an appropriate amendment hereto or a revised agreement setting forth new
economic and other 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 33 

 
terms and conditions meeting their mutual expectations, which renegotiation both Parties will attempt in good faith. If, despite their exercise of good faith efforts, the Parties are unable,
within such sixty (60) day period, to enter into a mutually acceptable agreement, this Agreement shall terminate effective on and as of the end of the ninety (90) day notice period. 

(vii) To the extent permitted by law, either Party may terminate this Agreement upon written notice to the other Party in the event of
(A) the entry of an order for relief under the United States Bankruptcy Code (or any corresponding remedy under successor laws) against the other Party, (B) the filing of a petition by or against the other Party under any bankruptcy,
insolvency, or similar law (which petition is not dismissed within sixty (60) days after filing), except Chapter 11 of the United States Bankruptcy Code or any successor statute that permits a corporation to continue its operation while
protecting it from creditors, (C) the appointment of a receiver for the other Party’s business or property, or (D) the other Party’s making of a general assignment for the benefit of its creditors. 

Section 8.3 Force Majeure 

Notwithstanding the provisions of Section 15.8, in the event of a failure of a Party to perform any of its
material obligations under this Agreement (including Zogenix’s supply obligations) by reason of a Force Majeure Event for a period of [***] consecutive days, (i) the other Party may terminate
this Agreement upon [***] written notice to the non-performing Party, or (ii) the other Party may have this Agreement continue in full force and effect without modification.

Section 8.4 Effect of Termination 
 (a) In the event of termination by Zogenix of this Agreement pursuant to Sections 8.2(b) or 8.2(c)(v), Zogenix [***]. In all circumstances of expiration or termination, no termination fee, penalty
or liquidated damages shall be owed to either Party by the other Party [***]. 
 (b) In the event of termination by
Zogenix pursuant to Sections 8.2(b) or 8.2(c)(v), Mallinckrodt [***]. 
 (c) In the event of expiration or termination
of this Agreement, (i) Mallinckrodt shall (A) immediately cease all Promotion in the Territory and (B) return all undistributed Samples and undistributed Promotional Materials [***] prior to such termination in an amount not to
exceed [***], except in the event of expiration of the Agreement or termination by Zogenix pursuant to Sections 8.2(b) or pursuant to the first sentence of Section 8.2(c)(v)) and (ii) the JSC and the JPT shall immediately be
disbanded. 
 (d) Expiration or termination of this Agreement shall not relieve either Party of any obligations accruing prior
to such expiration or termination. The following provisions of this Agreement by their terms continue after the expiration or termination of this 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 34 

 
Agreement: Sections 2.3, 3.5, 4.3, 4.4(f), 4.5(d) (first sentence), 4.5(f) (first sentence), 4.7 (with respect to the final [***]), 4.8, 4.9(a) (last sentence), 4.9(b) (last sentence),
5.4(b), 5.5, 5.6, 5.7 (with respect to Product distributed during the Term), 5.8 (last sentence), 7.1 (until all payments due are made and audit rights hereunder have expired), 7.2, 7.3, 7.4, 9.1 (to the extent necessary to give full effect to any
indemnification rights of Mallinckrodt hereunder), 9.2 (to the extent necessary to give full effect to any indemnification rights of Zogenix hereunder), 9.3 (with respect to Product and Samples delivered during the Term), 9.4, 9.5, 10.2, 10.3(b),
and this Section 8.4 and Articles I (for interpretational purposes), XI, XII, XIII, XIV and XV. In addition, any other provisions required to interpret and enforce the Parties’ rights and obligations under this Agreement shall also
survive, but only to the extent required for the interpretation and performance of this Agreement. 
 (e) Expiration or
termination of this Agreement shall be without prejudice to (i) any remedies which any Party may then or thereafter have hereunder or at law or in equity; (ii) a Party’s right to receive any payment accrued under the Agreement prior
to the termination date but which became payable thereafter and (iii) either Party’s right to obtain performance of any obligations provided for in this Agreement that survive termination by their terms or by a fair interpretation of this
Agreement. Except as expressly set forth herein, the rights to terminate as set forth herein and the consequences of such termination shall be in addition to all other rights and remedies available under this Agreement, at law or in equity, or
otherwise. 
 (f) Upon the expiration or termination of this Agreement pursuant to this Article VIII, each Party shall promptly
destroy or delete all embodiments, whether printed or electronic, of the Proprietary Information of the other Party in its control or possession or in the control or possession of its Affiliates, employees, officers, directors, agents, and
contractors (including, in the case of Mallinckrodt as the destroying Party, the Promotional Materials), and shall certify to the other Party as to such destruction and deletion. Notwithstanding the foregoing, the destroying Party may keep one
copy of such Proprietary Information or materials, as applicable, for archival purposes, and such copies of the foregoing as are required to be kept by Legal Requirements or the Party’s internal compliance policies, consistently applied, will
in all cases remain subject to the requirements of Article XII hereof. 
 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES 
 Section 9.1 Representations and Warranties of Zogenix 
 Zogenix
hereby represents and warrants to Mallinckrodt as of the date hereof, and covenants to Mallinckrodt, as follows: 
 (a)
Organization. Zogenix (i) is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware, and (ii) has all necessary corporate power and corporate authority to own its properties and
to conduct its business, as currently conducted. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 35 

 (b) Authorization. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby are within the corporate power of Zogenix, have been duly authorized by all necessary corporate proceedings of Zogenix, and this Agreement has been duly executed and delivered by Zogenix. 

(c) No Conflict. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby do
not: (i) conflict with or result in a breach of any provision of Zogenix’s organizational documents, (ii) result in a material breach of any material agreement to which Zogenix is Party, (iii) result in a violation of any
Order to which Zogenix is subject, (iv) require Zogenix to obtain any material approval or consent from any Governmental Authority or Third Party other than those consents and approvals which have been obtained prior to the date hereof or
(v) violate any Legal Requirement applicable to Zogenix in any material respect. 
 (d) Enforceability. This
Agreement constitutes the valid and binding obligation of Zogenix, enforceable against Zogenix in accordance with its terms, subject to bankruptcy, reorganization, insolvency and other similar laws affecting the enforcement of creditors’ rights
in general and to general principles of equity (regardless of whether considered in a proceeding in equity or an action at law). 
 (e) Zogenix Intellectual Property. To the knowledge of Zogenix, the manufacture and importation of the Product and the Promotion, offer for sale and sale of the Product in the Territory in
accordance with this Agreement do not and will not infringe any patents, Trademarks or other intellectual property rights of any Third Party; provided that Zogenix makes no representation as to the Mallinckrodt Trademarks. Zogenix has
not received any actual or threatened written claim or demand from any Third Party alleging that any infringement, violation or misappropriation of such Third Party’s intellectual property rights has occurred as a result of or in connection
with the manufacture, use, offer for sale, sale or importation of the Product in the Territory. Zogenix is not aware of any actual, alleged or threatened infringement, violation or misappropriation by a Third Party of any Zogenix intellectual
property rights covering the Product or its manufacture, use, offer for sale or sale. Zogenix has not received any actual or threatened written claim or demand from any Third Party alleging invalidity or unenforceability of any patents or patent
applications owned or otherwise Controlled by Zogenix covering the Product or its manufacture, use or sale. Zogenix is not aware of the filing by any Third Party of an Abbreviated New Drug Application with respect to the Product that contains a
Paragraph IV certification and Zogenix has not received any Paragraph IV Notice. 
 (f) Litigation. There is no
litigation, arbitration proceeding, governmental investigation, action or claims of any kind, pending or, to the knowledge of Zogenix, threatened, by or against Zogenix or any of its Affiliates relating to the Product or its manufacture,
importation, use, offer for sale or sale that would reasonably be expected to materially affect Zogenix’s or Mallinckrodt’s ability to perform its obligations hereunder. 

  
 36 

 (g) Generic Drug Act. Pursuant to the Generic Drug Enforcement Act of 1992, 21
U.S.C. § 335a, as it may be amended or supplemented (the “Generic Drug Act”), 
 (i) none of Zogenix, its
Affiliates or, to the knowledge of Zogenix, any Person under its direction or control is currently debarred by the FDA under the Generic Drug Act, 
 (ii) none of Zogenix, its Affiliates or, to the knowledge of Zogenix, any Person under its direction or control is currently using or will use in any capacity in connection with the Product any Person
that is debarred by FDA under the Generic Drug Act, and 
 (iii) there have been no convictions of Zogenix, its Affiliates, or,
to the knowledge of Zogenix, any Person under its direction or control for any of the types of crimes set forth in the Generic Drug Act within the five (5) years prior to the Effective Date. 

(h) Legal Requirements. None of Zogenix, its Affiliates or, to the knowledge of Zogenix, any Person under its direction or
control is currently or has been excluded from a federal or state health care program under Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 as it may be amended or supplemented. None of Zogenix, its
Affiliates or, to the knowledge of Zogenix, any Person under its direction or control is otherwise currently excluded or has otherwise been excluded from contracting with the federal government. None of Zogenix, its Affiliates or, to the
knowledge of Zogenix, any Person under its direction or control is otherwise currently or has otherwise been excluded, suspended or debarred from any federal or state program. Zogenix shall immediately notify Mallinckrodt if, at any time during
the Term, (x) Zogenix or its Affiliates is convicted of an offense that would subject Zogenix or Mallinckrodt to exclusion, suspension or debarment from any federal or state program, or (y) Zogenix becomes aware that any Person under the
direction or control of Zogenix or its Affiliates is convicted of an offense that would subject Zogenix or Mallinckrodt to exclusion, suspension or debarment from any federal or state program. 

(i) [***] 

Section 9.2 Representations and Warranties of Mallinckrodt 

Mallinckrodt hereby represents and warrants to Zogenix as of the date hereof, and covenants to Zogenix, as follows: 

(a) Organization. Mallinckrodt (i) is a limited liability company duly organized, validly existing and in good standing
under the laws of the state of Delaware and (ii) has all necessary corporate power and corporate authority to own its properties and to conduct its business, as currently conducted. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 37 

 (b) Authorization. The execution and delivery of this Agreement and the consummation
of the transactions contemplated hereby are within the corporate power of Mallinckrodt, have been duly authorized by all necessary corporate proceedings of Mallinckrodt, and this Agreement has been duly executed and delivered by Mallinckrodt.

 (c) No Conflict. The execution and delivery of this Agreement and the consummation of the transactions contemplated
hereby do not: (i) conflict with or result in a breach of any provision of Mallinckrodt’s organizational documents, (ii) result in a material breach of any material agreement to which Mallinckrodt is Party, (iii) result in a
violation of any Order to which Mallinckrodt is subject, (iv) require Mallinckrodt to obtain any material approval or consent from any Governmental Authority or Third Party other than those consents and approvals which have been obtained prior
to the date hereof or (v) violate any Legal Requirement applicable to Mallinckrodt in any material respect. 
 (d)
Enforceability. This Agreement constitutes the valid and binding obligation of Mallinckrodt, enforceable against Mallinckrodt in accordance with its terms, subject to bankruptcy reorganization, insolvency, and other similar laws affecting the
enforcement of creditors’ rights in general and to general principles of equity (regardless of whether considered in a proceeding in equity or an action at law). 
 (e) Mallinckrodt Trademarks. To the knowledge of Mallinckrodt, the use of the Mallinckrodt Trademarks in accordance with this Agreement will not infringe any trademarks or other intellectual
property rights of any Third Party. 
 (f) Litigation. There is no litigation, arbitration proceeding, governmental
investigation, action or claims of any kind, pending or, to the knowledge of Mallinckrodt, threatened, by or against Mallinckrodt or any of its Affiliates that would reasonably be expected to materially affect Mallinckrodt’s ability to perform
its obligations hereunder. 
 (g) Generic Drug Act. Pursuant to the Generic Drug Act, 

(i) none of Mallinckrodt, its Affiliates or, to the knowledge of Mallinckrodt, any Person under its direction or control is currently
debarred by the FDA under the Generic Drug Act, 
 (ii) none of Mallinckrodt, its Affiliates or, to the knowledge of
Mallinckrodt, any Person under its direction or control is currently using or will use in any capacity in connection with the Product any Person that is debarred by FDA under the Generic Drug Act, and 

(iii) there have been no convictions of Mallinckrodt, its Affiliates or, to the knowledge of Mallinckrodt, any Person under its
direction or control for any of the types of crimes set forth in the Generic Drug Act within the five years prior to the Effective Date. 
 (h) Legal Requirements. None of Mallinckrodt, its Affiliates or, to the knowledge of Mallinckrodt, any Person under its direction or control is currently excluded or has

  
 38 

 
been from a federal or state health care program under Sections 1128 or 1156 of the Social Security Act, 42 U.S.C. §§ 1320a-7, 1320c-5 as it may be amended or supplemented. None of
Mallinckrodt, its Affiliates or, to the knowledge of Mallinckrodt, any Person under its direction or control is otherwise currently excluded or has otherwise been excluded from contracting with the federal government. None of Mallinckrodt, its
Affiliates or, to the knowledge of Mallinckrodt, any Person under its direction or control is otherwise currently or has otherwise been excluded, suspended or debarred from any federal or state program. Mallinckrodt shall immediately notify
Zogenix if, at any time during the Term, (x) Mallinckrodt or its Affiliates is convicted of an offense that would subject Mallinckrodt or Zogenix to exclusion, suspension or debarment from any federal or state program, or (y) Mallinckrodt
becomes aware that any Person under the direction or control of Mallinckrodt or its Affiliates is convicted of an offense that would subject Mallinckrodt or Zogenix to exclusion, suspension or debarment from any federal or state program. 

Section 9.3 Product Warranty 
 Zogenix warrants to Mallinckrodt that: 
 (a) at the time of
delivery of all Product (excluding Samples delivered to Mallinckrodt hereunder) by or on behalf of Zogenix to a Third Party (including any delivery to a 3PL or any delivery by a 3PL on behalf of Zogenix to a wholesaler, other distributor or
retailer), (i) such Product will be in conformity with the applicable specifications therefor and the NDA, (ii) such Product will have been manufactured in compliance with cGMP and all other applicable Legal Requirements, (iii) such
Product will have been manufactured in facilities that are in compliance with all applicable Legal Requirements at the time of such manufacture (including applicable inspection requirements of FDA and other Governmental Authorities), (iv) such
Product will not be adulterated or misbranded under the Act, (v) such Product may be introduced into interstate commerce pursuant to the Act and (vi) the expiration date of such Product shall be no earlier than [***] after
the date of delivery thereof, and 
 (b) at the time of delivery of all Samples to Mallinckrodt hereunder,
(i) such Samples will be in conformity with the applicable specifications therefor and the NDA, (ii) such Samples will have been manufactured in compliance with cGMP and all other applicable Legal Requirements, (iii) such Samples will
have been manufactured in facilities that are in compliance with all applicable Legal Requirements at the time of such manufacture (including applicable inspection requirements of FDA and other Governmental Authorities), (iv) such Samples will
not be adulterated or misbranded under the Act, (v) such Samples may be introduced into interstate commerce pursuant to the Act and (vi) the expiration date of such Samples shall be no earlier than [***] after the date of delivery,
unless otherwise agreed in writing by Mallinckrodt . 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 39 

 Section 9.4 Zogenix Disclaimer 

EXCEPT AS EXPRESSLY PROVIDED HEREIN, ZOGENIX DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH REGARD TO THE PRODUCT,
INCLUDING ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTY OF NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 

Section 9.5 Mallinckrodt Disclaimer 

EXCEPT AS EXPRESSLY PROVIDED HEREIN, MALLINCKRODT DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF
MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTY OF NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. 
 ARTICLE X 
 INTELLECTUAL PROPERTY MATTERS 

Section 10.1 Intellectual Property Prosecution and Maintenance 

Zogenix shall, at its own expense, use commercially reasonable efforts to prosecute and maintain all Zogenix intellectual property in the
Territory (including patents, the Zogenix Trademarks and any copyrights associated with the Promotional Materials) related to the Product or its manufacture, use, offer for sale or sale. Zogenix shall [***] regarding the ongoing prosecution
and maintenance of Zogenix patents to the extent they relate to the Product or its manufacture, use or sale in the Territory, including all office actions and notices of allowance. 

Section 10.2 Ownership 

Zogenix shall own all intellectual property rights in and to the regulatory and clinical data (but not commercial data
generated in the course of performance hereunder) or other inventions and improvements incorporated into the Product, including any such inventions and improvements related to the “DosePro” delivery device incorporated into the Product, in
each case conceived or reduced to practice by either Party pursuant to this Agreement. In addition, during the Term and [***], Mallinckrodt shall [***]. Each Party shall own all intellectual property rights with respect to
commercial data generated by or on behalf of it in the course of performance hereunder. 
 Section 10.3
Infringement 
 (a) If either Party shall learn of a claim or assertion that the manufacture, use or sale of the
Product in the Territory infringes or otherwise violates the intellectual property rights of any Third Party or that any Third Party violates the intellectual property rights owned or Controlled by (i) Zogenix in the Product or the Zogenix
Trademarks in the Territory or (ii) Mallinckrodt in the Mallinckrodt Trademarks, then the Party becoming so 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 40 

 
informed shall promptly, but in all events within [***] thereof, notify the other Party to this Agreement of the claim or assertion. In the event Zogenix receives a notice under Paragraph
IV of the U.S. Federal Drug Price Competition and Patent Term Restoration Act of 1984, as amended, also known as the Hatch-Waxman Act, with respect to the Product, Zogenix shall provide Mallinckrodt with written notice of such Paragraph IV notice
[***] (each, a “Paragraph IV Notice”). 
 (b) In the event of any infringement of
Zogenix patent rights related to the Product or its manufacture, use or sale, or the Zogenix Trademarks in the Territory, which infringement involves a product that could or does compete with the Product or could adversely affect the Parties’
interests in the Product under this Agreement, Zogenix shall, in its sole discretion determine to take the appropriate legal action (as to any Party to redress a Third Party infringement, an “Enforcement Action”), if any. In the
event such an Enforcement Action is initiated, Zogenix shall use commercially reasonable efforts to prosecute such matter and shall [***]. At Zogenix’s reasonable request, Mallinckrodt shall cooperate fully with Zogenix with respect
to any such Enforcement Action, and Zogenix shall [***]. Any recovery received as a result of any Enforcement Action
[***], and any amounts remaining thereafter allocable as compensation for [***] during the Term shall be [***] to Mallinckrodt and [***] to Zogenix. 

(c) In the event of an Enforcement Action by Mallinckrodt with respect to any Mallinckrodt Trademark, at Mallinckrodt’s reasonable
request, Zogenix shall cooperate fully with Mallinckrodt with respect to any such Enforcement Action, and Mallinckrodt shall reimburse Zogenix for its reasonable out-of-pocket expenses incurred in providing such cooperation. Any recovery achieved by
Mallinckrodt with respect to such Enforcement Action shall be solely for the account of Mallinckrodt. 
 ARTICLE XI

 INDEMNIFICATION; LIMITS ON LIABILITY 

Section 11.1 Indemnification 
 (a) Subject to the applicable provisions of this Article XI, each Party (each, an “Indemnifying Party”) shall defend, at its own expense, indemnify and hold harmless the other Party (the
“Indemnified Party”) and its Affiliates, and its and their respective directors, officers, employees, agents, Sales Representatives and other representatives (collectively, the “Indemnified Persons” of the
Indemnified Party), from and against any and all damages, liabilities, losses, costs, and expenses, including reasonable attorneys’ fees and reasonable expert fees and expenses (“Loss”) arising out of any Third Party claim,
suit or proceeding (“Claim”) brought against the Indemnified Party or its Indemnified Persons to the extent such Claim arises out of or relates to (i) any breach or violation by the Indemnifying Party of, or failure to perform
by the Indemnifying Party of, any representation, warranty, covenant or other obligation in this Agreement, unless waived in writing by the Indemnified Party, (ii) the negligence or willful misconduct of the Indemnifying Party or any of its
Indemnified Persons or its Third Party 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 41 

 
contractors (including Third Party manufacturers or suppliers), (iii) any violation of applicable Legal Requirements by the Indemnifying Party or any of its Indemnified Persons or its Third
Party contractors (including Third Party manufacturers or suppliers) and (iv) any actions of the Indemnifying Party’s Sales Force or scientific liaisons, including any false or misleading representations to Professionals, customers or
others regarding the Indemnified Party or the Product or any Promotion by the Sales Representatives of the Indemnifying Party for “off-label” indications; excluding, in each case (i.e., (i), (ii), (iii) and (iv)), any Loss for which
the Indemnified Party has an obligation to indemnify the Indemnifying Party or its Indemnified Persons pursuant to this Section 11.1, as to which Loss each Party shall indemnify the other to the extent of their respective liability for such
Loss. 
 (b) In addition, Zogenix shall defend, at its own expense, indemnify, and hold harmless Mallinckrodt and its
Indemnified Persons, from and against Losses arising out of Claims brought against Mallinckrodt or its Indemnified Persons to the extent such Claim arises out of or relates to (i) any claim made by any Person that the manufacture, use, sale or
offer for sale of the Product infringes or misappropriates the patent, trademark or other intellectual property rights of such Person, except with respect to any claim relating to the Mallinckrodt Trademarks, (ii) any claim for products
liability with respect to the Product (e.g., any Claim alleging that the use of the Product has caused any Adverse Drug Experience, Serious Adverse Drug Experience or other injury, or that the labeling of the Product fails properly or fully to warn
users or prescribers of the risks associated with use of the Product), regardless of the legal theory upon which any such claim is based and except to the extent liability is caused by a breach by Mallinckrodt of Sections 4.3 or 5.3(a) (and in the
event any claim is caused in part by Mallinckrodt’s breach of Sections 4.3 or 5.3(a), each Party shall indemnify the other to the extent of their respective liability for Loss associated with such claim), (iii) without limitation of clause
(ii), any claim based on death, personal injury or property damage arising out of the manufacture of the Product by or on behalf of Zogenix (including such manufacture of supply by Third Party manufacturers or suppliers), except to the extent
liability is caused by a breach by Mallinckrodt of Sections 4.3 or 5.3(a) (and in the event any claim is caused in part by Mallinckrodt’s breach of Sections 4.3 or 5.3(a) each Party shall indemnify the other to the extent of their respective
liability for Loss associated with such claim), (iv) any claim alleging that the Promotional Materials make false, misleading, unlawful or unsupported claims about the Product or otherwise violate applicable Legal Requirements and (v) any
decision taken hereunder with respect to which Zogenix or its officers or representatives had final decision-making authority, including those disputes over the determination of WAC or the amount of Deductions, which disputes are to be resolved
pursuant to Section 3.5(ii). 
 (c) The Indemnified Party shall promptly notify the Indemnifying Party in writing of any
Claim and shall give the Indemnifying Party full information and assistance in connection therewith. The Indemnifying Party’s obligation to defend, indemnify and hold harmless any Indemnified Person shall be reduced or eliminated to the extent
the Indemnified Party’s delay in providing notification pursuant to the previous sentence results in prejudice to the Indemnifying Party. The Indemnifying Party shall have the sole right to control the defense and the sole right to settle
or compromise the Claim, except that the prior written consent of the Indemnified Party shall be required in connection with any settlement or compromise that could (i) place any obligation on or require any action on the part of the
Indemnified Party or its Indemnified Persons, or (ii) admit or imply any liability or wrongdoing 

  
 42 

 
on the part of the Indemnified Party or its Indemnified Persons. Notwithstanding the foregoing, the Indemnified Party may participate in such defense through counsel of its choice, but the
cost of such counsel shall be borne solely by the Indemnified Party. 
 Section 11.2 Consequential
Damages 
 NEITHER MALLINCKRODT NOR ZOGENIX, NOR THEIR RESPECTIVE AFFILIATES, NOR THEIR RESPECTIVE
DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS (OR THE DIRECTORS, OFFICERS, EMPLOYEES OR AGENTS OF THEIR AFFILIATES) SHALL HAVE ANY LIABILITY TO THE OTHER PARTY (OR TO THE OTHER PARTY’S AFFILIATES OR ITS OR THEIR DIRECTORS,
OFFICERS, EMPLOYEES, OR AGENTS) FOR ANY PUNITIVE DAMAGES, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES, RELATING TO OR ARISING FROM THIS AGREEMENT, WHETHER OR NOT ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND EVEN IF SUCH DAMAGES
MAY HAVE BEEN REASONABLY FORESEEABLE; PROVIDED THAT SUCH LIMITATION SHALL NOT APPLY (A) IN THE CASE OF EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 11.1, OR (B) IN THE CASE OF FRAUD, GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT. 
 ARTICLE XII 
 CONFIDENTIALITY AND PUBLICITY 
 Section 12.1
Proprietary Information 
 A Party receiving Proprietary Information from the other, directly or indirectly, will
treat such Proprietary Information as confidential, will use such Proprietary Information only for the purposes of this Agreement, and will not disclose, and will take all reasonable precautions to prevent the disclosure of, such Proprietary
Information to (i) any of its Affiliates or its or their officers, directors, managers, equity holders, employees, agents, representatives or consultants, except those who reasonably need to know such Proprietary Information in order for such
Party to exercise its rights or fulfill its obligations under this Agreement and who are bound by a like obligation of confidentiality or (ii) to Third Parties. In protecting the Proprietary Information of the disclosing Party from improper use
of disclosure, the receiving Party shall use at least the same degree of care that it employs in protecting its own similar information, but in any event no less than a reasonable degree of care. 

Section 12.2 Disclosures Required by Law 

If a Party that is the recipient of Proprietary Information of the other Party is required under applicable Legal Requirements to disclose
such Proprietary Information (i) to any Governmental Authority to obtain any Regulatory Approval for the Product, (ii) in connection with bona fide legal process (including in connection with any bona fide dispute hereunder) or
(iii) under the rules of the securities exchange upon which its securities are traded, then the recipient Party may do so only if (A) it limits disclosure of the Proprietary Information only to that information required to be disclosed,
(B) it limits disclosure to that purpose, and (C) except in the case of clause (ii) in circumstances involving a bona fide dispute hereunder, it gives the disclosing Party, if practicable under the circumstances, prompt written notice
of any instance of 

  
 43 

 
such a requirement in reasonable time for the disclosing Party to attempt to object to or to limit such disclosure. With respect to disclosures required under applicable Legal Requirements,
the recipient Party shall cooperate with the disclosing Party as reasonably requested thereby, consistent with such Legal Requirements. 
 Section 12.3 Publicity 
 The Parties have agreed
upon the form and content of a press release(s) to be issued promptly following the execution of this Agreement. Once such press release(s) or any other written statement is approved for disclosure by both Parties, either Party may make subsequent
public disclosure of the contents of such statement (if such contents remain accurate and not misleading) without the further approval of the other Party. Any other publicity, news release, public comment or other public announcement, whether to the
press, to stockholders, or otherwise, relating to this Agreement, including activities conducted hereunder, shall first be reviewed and approved by both Parties (such approval not to be unreasonably withheld or delayed), except no such approval
shall be required for such publicity, news release, public comment or other public announcement which, in accordance with the advice of legal counsel to the Party making such disclosure, is required by law or for appropriate market disclosure. For
clarity, any Party making any announcement which is required by law will, unless prohibited by law, give the other Party an opportunity to review the form and content of such announcement and comment before it is made, and shall, if possible under
applicable circumstances, provide the other Party
[***] advance written notice of any such announcement. The Parties shall work together to coordinate filings with governmental agencies, including the United States Securities and Exchange Commission, as to
the contents and existence of this Agreement as the Parties shall reasonably deem necessary or appropriate, and each Party shall provide the other Party an opportunity to comment on any proposed filings, including redactions proposed thereto.

 Section 12.4 Survival 

The provisions of this Article XII shall survive termination of this Agreement and shall remain in effect until a date [***] after
the expiration or termination of this Agreement. 
 ARTICLE XIII 

NOTICES 
 Section 13.1 Notices 
 Subject to Section 3.4(e) (governing
certain communications relating to the day-to-day business of a Committee), all notices required or permitted hereunder shall be given in writing and sent by facsimile transmission (with a copy sent by first-class mail), mailed postage prepaid by
certified or registered mail (return receipt requested), sent by a nationally recognized express courier service, or hand-delivered at the addresses below or to such other address as the addressee shall have last furnished to the addressor in a
manner consistent with the requirements of this Section 13.1: 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 44 

 If to Zogenix: 

Zogenix, Inc. 
 12400 High Bluff Drive 
 Suite 650 

San Diego, CA 92130 
 Attention: Chief Financial Officer 
 Fax
No: (858) 259-1166 
 With a copy to (which shall not constitute notice hereunder): 

Latham & Watkins LLP 
 12636 High Bluff Drive 
 Suite 400 

San Diego, CA 92130 
 Attention: Faye H. Russell 
 Fax No: (858) 523-5450

 If to Mallinckrodt: 
 Mallinckrodt LLC 
 675 McDonnell Boulevard 

Hazelwood, MO 63042 
 Attention: 
 Fax No: 

With a copy to (which shall not constitute notice hereunder): 

Mallinckrodt LLC 
 675 McDonnell Boulevard 
 Hazelwood, MO 63042 

Attention: C. Stephen Kriegh, VP-Legal 

Fax No: (314) 654-7181 
 All notices shall be deemed made upon receipt by the addressee. 

  
 45 

 ARTICLE XIV 
 INSURANCE 
 Section 14.1 Insurance

 (a) During the Term and for a period of [***] after any expiration or termination of this
Agreement, each Party shall obtain and maintain at its own expense from an insurance company rated [***] (i) a commercial general liability insurance policy or policies with minimum limits of [***] and [***] on an annual basis,
and (ii) a product liability insurance policy or policies with minimum limits of [***] and [***] on an annual basis. Such policies shall, as applicable to a Party and its obligations under Article XI (but, for clarity, not in
limitation of any such obligations), include protection against claims, demands and causes of action arising out of any defects or failure to perform, alleged or otherwise, of the Product or any material used in connection therewith or any use
thereof. Notwithstanding the foregoing, either Party may satisfy its obligations under this Section 14.1, in whole or in part, through a program of self-insurance that is reasonably satisfactory to the other Party; provided that at the
request of the other Party, such Party shall provide reasonably satisfactory evidence of the nature of its self-insurance program. If one Party reasonably determines that the other Party’s program of self insurance is not satisfactory, the
Parties will meet to address any issues and concerns. 
 (b) Each Party shall furnish, at the request of the other
Party, a certificate of insurance evidencing that such insurance is in effect. Each Party will provide the other Party [***] days’ prior written notice of cancellation or non-renewal in the insurance required by this Agreement. Neither
Party’s liability to the other is in any way limited to the extent of its insurance coverage. 
 ARTICLE XV

 MISCELLANEOUS 
 Section 15.1 Dispute Resolution 
 (a) The Parties hereby agree that
they will attempt in good faith to resolve any controversy or claim arising out of or relating to this Agreement promptly by negotiations and, where specifically provided for, in accordance with any specific provisions for dispute resolution set
forth elsewhere in this Agreement with respect to any particular matter or Section hereof. If a controversy or claim should arise hereunder, and if a dispute resolution provision is not otherwise provided herein for settlement of such controversy or
claim, appropriate representatives of the Parties will confer at least once and will attempt to resolve the matter. Except as specifically provided elsewhere in this Agreement, if the matter has not been resolved within [***] of their first
meeting, the representatives shall refer the matter to appropriate Commercial Officers. If the matter has not been resolved within [***] after referral to the Parties’ Commercial Officers, any controversy or claim arising out of or
relating to this Agreement may be settled as set forth in Section 15.1(b) set forth immediately below, if both Parties agree. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 46 

 (b) If and as the Parties agree to submit any dispute to arbitration
which has not been resolved as set forth in Section 3.5 or any other relevant provision hereof, such dispute shall be settled by binding arbitration in accordance with the Judicial Arbitration and Mediation Services (“JAMS”)
Comprehensive Arbitration Rules and Procedures, as such rules may be modified by this Section 15.1(b) or by agreement of the Parties. The Parties shall mutually select a single independent, conflict-free arbitrator, who shall have sufficient
background and experience to resolve the matter in dispute. If the Parties are unable to reach agreement on the selection of the arbitrator within [***] after submission of a dispute to arbitration, then either
or both Parties shall immediately request JAMS to select an arbitrator with the requisite background, experience and expertise. Notwithstanding the applicable JAMS rules, (i) the arbitrator shall resolve the dispute as expeditiously as
reasonably possible, and in any event no later than [***] following referral of the dispute to the arbitrator and (ii) the arbitrator shall resolve the dispute in a manner that is fair and reasonable to the Parties in light of the
totality of the circumstances and the terms of this Agreement. The place of arbitration shall be [***], and all proceedings and communications shall be in English. Either Party may apply to the arbitrator for interim injunctive relief or may
seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending resolution of the matter pursuant to this Section 15.1(b). The Parties shall have the right to be
represented by counsel. Any judgment or award rendered by the arbitrator shall be final and binding on the Parties, and shall be governed by the terms and conditions hereof, including the limitation on damages set forth in Section 11.2. The
Parties agree that such a judgment or award may be enforced in any court of competent jurisdiction. The statute of limitations of the [***] applicable to the commencement of a lawsuit shall apply to the commencement of arbitration under this
Section 15.1(b). Each Party shall bear its own costs and expenses and attorneys’ fees and, unless otherwise agreed by the Parties or determined by the arbitrator, the Party that does not prevail in the arbitration proceeding shall pay the
arbitrator’s fees and any administrative fees of arbitration. All proceedings and decisions of the arbitrator(s) shall be deemed Proprietary Information of each of the Parties, and shall be subject to Article XII. For the avoidance of doubt,
disputes arising on issues within the jurisdiction of a Committee shall be resolved in accordance with the procedures set forth in Section 3.5, and any dispute arising hereunder for which there is a specific dispute resolution procedure
provided herein which is expressly intended to be final shall only be settled by application of such procedure and not by resort to the dispute resolution procedures set forth in this Section 15.1. 

Section 15.2 Headings 
 The titles, headings or captions and paragraphs in this Agreement are for convenience only and do not define, limit, extend, explain or describe the scope or extent of this Agreement or any of its terms
or conditions and therefore shall not be considered in the interpretation, construction or application of this Agreement. 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 47 

 Section 15.3 Severability 

Should one or more provisions of this Agreement be or become invalid or unenforceable, the Parties hereto shall substitute, by mutual
consent, valid and enforceable provisions for such invalid or unenforceable provisions which new provisions, in their economic and other effects, are sufficiently similar to the invalid or unenforceable provisions that it can be reasonably assumed
that the Parties would have originally entered into this Agreement with such new provisions. In case such new provisions cannot be agreed upon, the invalidity or unenforceability of one or several provisions of this Agreement shall not affect the
validity of this Agreement as a whole or the validity of any portions hereof, unless the invalid or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably assumed that one or both of the Parties would
not originally have entered into this Agreement without such invalid or unenforceable provisions. 
 Section
15.4 Entire Agreement 
 This Agreement, together with the schedules and exhibits hereto and the documents referred
to herein, all of which are incorporated by reference, contains all of the terms agreed to by the Parties regarding the subject matter hereof and supersedes any prior agreements, understandings or arrangements between them, whether oral or in
writing. For the avoidance of doubt, the Confidentiality Agreement is superseded with respect to the subject matter hereof. 
 Section 15.5 Amendments 
 This Agreement may not be amended,
modified, altered or supplemented except by means of a written agreement or other instrument executed by both of the Parties hereto. No course of conduct or dealing between the Parties will act as a modification or waiver of any provisions of
this Agreement. 
 Section 15.6 Counterparts 

This Agreement may be executed in any number of counterparts, each of which will be deemed an original as against the Party whose
signature appears thereon, but all of which taken together will constitute but one and the same instrument. 

Section 15.7 Waiver 
 The failure of either Party to enforce or to exercise, at any time or for any period of time, any term of or any right arising pursuant to this Agreement does not constitute, and will not be construed as,
a waiver of such term or right, and will in no way affect that Party’s right later to enforce or exercise such term or right or to enforce or insist upon performance of any other provision hereof. 

Section 15.8 Force Majeure 
 (a) In the event of any failure or delay in the performance by a Party of any obligation under this Agreement due to events beyond the reasonable control of such

  
 48 

 
Party (such as, for example, fire, explosion, strike, inability to obtain transportation, fuel, or power, accident, act of God, declared or undeclared wars, or acts of terrorism) (a
“Force Majeure Event”), then such Party shall have such additional time to perform as shall be reasonably necessary under the circumstances. For clarity, a Force Majeure Event shall not include a failure to commit sufficient
resources, financial or otherwise, to the performance of obligations under this Agreement or general market or economic conditions not accompanied by circumstances of the type described in the first sentence of this Section 15.8. In the event
of such failure or delay, the affected Party will use its diligent efforts, consistent with sound business judgment and to the extent permitted by Legal Requirements, to correct and mitigate such failure or delay as expeditiously as
possible. In the event that a Party is unable to perform by a reason described in this Section 15.8, its obligation to perform under the affected provision of this Agreement shall be suspended during such time of nonperformance.

 (b) Neither Party shall be liable hereunder to the other Party nor shall be in breach for failure to
perform its obligations caused by a Force Majeure Event unless and to the extent it fails to comply with its obligations under the third sentence of Section 15.8(a) above and, further, as long as the occurrence of any Force Majeure Event is not
itself the result of any acts or omissions to act by a Party so affected that do not themselves constitute a Force Majeure Event. In the case of any such Force Majeure Event, the affected Party shall promptly, but in no event later than
[***] after its occurrence, notify the other Party stating the nature of the condition, its anticipated duration, and any action being taken to avoid or minimize its effect. Furthermore, the affected
Party shall keep the other Party informed of the efforts to resume performance. After [***] of such inability to perform, the Parties shall meet and discuss in good faith how to proceed. 

Section 15.9 Successors and Assigns 

Subject to Section 15.10, this Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their
respective successors and assigns permitted under this Agreement. 
 Section 15.10 Assignment

 (a) This Agreement and the rights granted herein shall not be assignable (or otherwise transferred) by either Party hereto
without the prior written consent of the other Party. Any attempted assignment without consent shall be void. Notwithstanding the foregoing, a Party may transfer, assign or delegate its rights and obligations under this Agreement without
consent to (i) an Affiliate reasonably capable of performing such Party’s obligations under this Agreement, or (ii) a successor to all or substantially all of its business or assets of the assigning Party to which this Agreement
relates, whether by sale, merger, consolidation, acquisition, transfer, operation of law or otherwise. [***]. For the avoidance of doubt, any such assignment in connection with a Change of Control, whether permitted or not hereunder, shall
not affect the right of any Party to terminate this Agreement as a consequence of a Change of Control of either Party pursuant to and in accordance with Section 8.2(c)(iii). 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 49 

 (b) In connection with (i) any assignment pursuant to this Section 15.10 of this
Agreement or any of the rights granted herein, or (ii) any subcontract permitted hereunder, the assignor or Party subcontracting shall ensure that the assignee or subcontractor represents and warrants the matters set forth (x) in Sections
9.1(g) and 9.1(h) (in substantially the same form as set forth in Sections 9.1(g) and 9.1(h)) where Zogenix (or one of its successors or assigns) is the assignor or subcontracting Party, or (y) in Sections 9.2(g) and 9.2(h) (in substantially
the same form as set forth in Sections 9.2(g) and 9.2(h)), where Mallinckrodt (or one of its successors or assigns) is the assignor or subcontracting Party. Neither Party shall engage any Third Party appearing on the FDA’s debarment list
or the list of excluded individuals/entities of the Office of Inspector General of the Department of Health and Human Services to perform, or assist such Party in the performance of, its obligations under this Agreement, and each Party shall review
each such list prior to so engaging any Third Party. 
 Section 15.11 Construction 

The Parties acknowledge and agree that: (i) each Party and its representatives have reviewed and negotiated the
terms and provisions of this Agreement and have contributed to its revision and (ii) the terms and provisions of this Agreement will be construed fairly as to each Party hereto and not in favor of or against either Party regardless of which
Party was generally responsible for the preparation or drafting of this Agreement. Unless the context of this Agreement otherwise requires: (v) words of any gender include each other gender, (w) words using the singular or plural
number also include the plural or singular number, respectively, (x) the terms “hereof,” “herein,” “hereby,” and derivative or similar words refer to this entire Agreement, (y) the terms “Article,”
“Section,” “Exhibit,” “Schedule,” or “clause” refer to the specified Article, Section, Exhibit, Schedule, or clause of this Agreement, and (z) the term “including” or “includes” means
“including without limitation” or “includes without limitation.” Whenever this Agreement refers to a number of days, such number shall refer [***]. 

Section 15.12 Governing Law 
 This Agreement will be construed under and in accordance with, and governed in all respects by, the laws of the State of New York, without regard to its conflicts of law principles. 

Section 15.13 Equitable Relief 
 Each Party acknowledges that a breach by it of its obligations under Section 2.3, and Article XII may not reasonably or adequately be compensated in damages in an action at law, and that such a
breach may cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party is entitled to seek, in addition to any other remedies it may have under this Agreement or otherwise, preliminary and
permanent injunctive and other equitable relief to prevent or curtail any breach of such Section and Article of this Agreement by the other Party; provided, however, that no specification in this Agreement of a specific legal or equitable
remedy will be construed as a waiver or prohibition against the pursuing of other legal or equitable remedies in the event of such a breach. Each Party agrees 

  

	***	 Certain
information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 50 

 
that the existence of any claim, demand or cause of action of it against the other Party, whether predicated upon this Agreement, or otherwise, will not constitute a defense to the enforcement by
the other Party, or its successors or assigns, of the covenants contained in this Agreement. 
 Section 15.14
Relationship Between Parties 
 The Parties hereto are acting and performing as independent contractors, and
nothing in this Agreement creates the relationship of partnership, joint venture, sales agency, or principal and agent. Neither Party is the agent of the other, and neither Party may hold itself out as such to any other Person. All
financial obligations associated with each Party’s business will be the sole responsibility of such Party. 
 [Signature
page follows] 

  
 51 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed in duplicate
effective on the day and year first above written. 
  

			
	ZOGENIX, INC.
		
		 	 /s/ Roger Hawley

	 By:
	 	Roger Hawley
	 Its:
	 	C.E.O.
	
	MALLINCKRODT LLC
		
		 	 /s/ Peter Edwards

	 By:
	 	Peter Edwards
	 Its:
	 	VP and General Counsel

  
 52Commercial Outsourcing Services Agreement

 Exhibit 10.1 
 COMMERCIAL OUTSOURCING SERVICES AGREEMENT 
 This Commercial Outsourcing
Services Agreement (“Agreement”) is entered into as of April 14, 2011 (the “Effective Date”) by INTEGRATED COMMERCIALIZATION SOLUTIONS, INC., a California corporation (“ICS”) and Corcept Therapeutics,
INC., a Delaware corporation (the “Company”). 
 RECITALS 

A. Company is, among other things, in the business of manufacturing, selling and distributing pharmaceutical products, including those listed on Schedule
A (“Products”); 
 B. ICS is, among other things, in the business of providing commercialization services for pharmaceutical products;

 C. The Company desires to engage ICS as its agent to provide certain commercialization services related to Products pursuant to this
Agreement; and 
 D. ICS desires to provide such commercialization services to the Company as its agent pursuant to this Agreement. 

AGREEMENT 

NOW, THEREFORE, the parties hereby agree as follows: 
  

	1.	Appointment As Exclusive Agent 

 The Company hereby appoints ICS as the exclusive provider of Services (as defined in Section 2) for Products sold to the Company’s customers (“Customers”) in the United States, Guam,
Puerto Rico and the U.S. Territories during the Term (as defined in Section 4.1), as provided in this Agreement. 
  

	2.	Services To Be Performed 

2.1 Services. The Company hereby engages ICS to provide the following services with respect to Products (“Services”):

 2.1.1 Customer Services as described in Exhibit B. 

2.1.2 Warehousing and Inventory Program Services as described in Exhibit C. 

2.1.3 Distribution Services as described in Exhibit D. 
 2.1.4 Warehousing and Distribution of Sample Products as described in Exhibit E. 
 2.1.5 Marketing Materials Fulfillment Services as described in Exhibit F. 

2.1.6 Contract Administration and Chargeback Processing as described in Exhibit G. 

2.1.7 Accounts Receivable Management and Cash Applications as described in Exhibit H. 

2.1.8 Financial Management Services as described in Exhibit I. 

2.1.9 Information Technology Services as described in Exhibit J. 

  
 Page 1

  

 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits
the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 2.2 ADR Status. Solely for the limited purpose of compliance with the pedigree
requirements of the Prescription Drug Marketing Act and any similar state laws, ICS shall be considered an “Authorized Distributor of Record” for the Products and a third party logistics provider who does not take title to Product or have
general responsibility to direct the Product’s sale or disposition. The foregoing shall not be construed in a manner that results in ICS being considered a distributor or wholesaler for any other purpose or under any other law or regulation.

 2.3 Taxes. ICS will not be responsible for collection or payment of any Taxes on behalf of the Company. 

2.4 Definitions. Capitalized words used without definition in this Agreement will each have the meaning in Schedule C Capitalized
words used without definition in this Agreement will each have the meaning in Schedule C. 
  

	3.	Compensation - Fees For Services 

 3.1 Compensation. The Company will compensate ICS for Services in accordance with Schedule B. ICS will provide monthly invoices for fees for Services to the Company, and will bill the
Company for any pass through charges monthly or as ICS is billed. The Company will notify ICS of any disputed charges in writing within 30 days of the date of the invoice covering such charges. In the absence of any such notice of dispute, all
invoices will be deemed to be correct and due in full within 30 days of the invoice date. If the Company disputes a portion of an invoice, the Company shall pay the undisputed portion of the invoice within 30 days of the invoice date. A late fee of
[***] per month (or any portion thereof) will be charged as of the due date on all amounts not paid within [***] days of the invoice date, except any amount disputed by the Company in good faith. If any dispute is resolved in favor of ICS, the
Company will pay the applicable late fee on such amount from the original due date. 
 3.2 Cost Adjustment. If ICS can
reasonably demonstrate to the Company that the costs to ICS for providing Services have materially increased (or are reasonably likely to increase materially during the following twelve (12) month period of the Term) as a result of any changes
to the contemplated distribution model (including a move to direct-to-physician or drop-ship model) or changes in the Requirements of Law, including the adoption of any new Requirements of Law impacting Services, then ICS may increase the applicable
component of the fees for such Services provided in Schedule B (“Cost Adjustment”). ICS will notify the Company of any proposed Cost Adjustment at least [***] days prior to its effective date. All Cost Adjustments will be determined under
generally accepted accounting principles (GAAP) and cost allocation methods applied on a consistent basis. If the Company objects to any Cost Adjustment and the parties are unable in good faith to resolve such objection to the reasonable
satisfaction of both parties, then either party may terminate this Agreement upon [***] days’ prior written notice to the other party. 
 3.3 Program Ready Date. If the Company requests that ICS delay the launch of Services [***] days beyond the agreed-upon date on the signatory page (the “Program Launch Date”), the Company
will pay ICS a program ready fee and any associated expenses as specified in Schedule B, including reasonable out-of-pocket costs and other expenses. The Company will give ICS at least [***] written notice of changes to the Program Launch Date.
Program ready fees will continue until the Program Launch Date. After the Program Launch Date, the Company will pay applicable monthly program fees. For the first month during which Services are provided, ICS will prorate any difference between
program ready fees and applicable monthly program fees. 

  
 Page 2

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	4.	Term And Termination 

 4.1
Initial Term. This Agreement will be effective as of the Effective Date and will continue for three (3) years (the “Term”) unless sooner terminated in accordance with Section 4. The Term may be extended upon written mutual
agreement of the parties, such extension to be negotiated in good faith six (6) months prior to the expiration of the Term. 
 4.2 Termination For Breach. 
 4.2.1 If a party fails to pay any amount due
to the other party under this Agreement, the other party may provide notice to the non-paying party specifying the amount due and notifying the non-paying party that the other party may terminate this Agreement if the non-paying party fails to pay
the amount due within [***] days of the date of the notice. If the non-paying party fails to pay the amount due within [***]days of the date of the notice, the other party may terminate this Agreement immediately and, in such event, shall provide
written notice thereof to the non-paying party; provided that if such breach occurs more than [***] times during any [***] period, the non-breaching party may terminate this Agreement upon [***] days’ written notice without any
opportunity for cure. 
 4.2.2 If a party fails to perform any other material obligation under this Agreement, the other party
may provide notice to the breaching party describing the breach in detail and notifying the breaching party that the other party may terminate this Agreement if the breaching party’s failure to perform is not cured within [***]days of the date
of the notice. If the breaching party’s failure to perform is not cured within [***] days of the date of the notice, then the other party may terminate this Agreement immediately and, in such event, shall provide written
notice thereof to the breaching party; provided that (i) if the breaching party has begun to cure a non-monetary breach within such [***] days, but such cure is not completed within such [***] days, the breaching party will have a
reasonable time to complete its cure if it diligently pursues the cure until completion, and (ii) if such breach occurs more than [***] times during any [***]period, the non-breaching party may terminate this Agreement upon [***] days’
written notice without any opportunity for cure. 
 4.3 Termination For Specific Events. Either party may immediately
terminate this Agreement upon written notice to the other party upon the other party’s: (a) filing an application for or consenting to appointment of a trustee, receiver or custodian of its assets; (b) having an order for relief
entered in Bankruptcy Code proceedings; (c) making a general assignment for the benefit of creditors; (d) having a trustee, receiver, or custodian of its assets appointed unless proceedings and the person appointed are dismissed within
[***] days; (e) dissolving its existence under applicable state law; (f) insolvency within the meaning of Uniform Commercial Code Section 1-201 or failing generally to pay its debts as they become due within the meaning of Bankruptcy
Code Section 303(h)(1), as amended; or (g) certification in writing of its inability to pay its debts as they become due (and either party may periodically require the other to certify its ability to pay its debts as they become due)
(each, a “Bankruptcy Event”). Each party agrees to provide immediate notice to the other party upon a Bankruptcy Event. 
 4.4 Expenses. Within [***] days of expiration or earlier termination of this Agreement for any reason, the Company will (a) pay ICS any amount owed; (b) return to ICS all hardware,
software and other equipment, or pay to ICS the replacement cost of items not returned; and (c) pay non-recoverable expenses for telecommunication, facsimile, postage, shipping and other services incurred by ICS up to the effective date of
termination. 
 4.5 Survival. Accrued payment, indemnity and confidentiality obligations, and any provision if its
context shows that the parties intended it to survive, will survive expiration or termination of this Agreement and, except as expressly provided, expiration or termination will not affect any obligations arising prior to the expiration or
termination date. 

  
 Page 3

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	5.	Recalls; Other FDA Issues 

5.1 Recalls. If the Company conducts a recall, market withdrawal or field correction of any Products (“Recall”), the
Company will conduct the Recall or designate a third party to do so and be responsible for all Recall expenses. ICS will comply with the Company’s reasonable requests in the Recall. If the Recall was not due primarily to ICS’s negligence,
the Company will pay or reimburse ICS’s Recall expenses (including reasonable attorneys’ fees). If the Recall was due primarily to ICS’s negligence, ICS will pay or reimburse the Company’s reasonable documented out-of-pocket
Recall expenses (including reasonable attorneys’ fees). Each party will use its best efforts to minimize Recall expenses. The Company will notify ICS of any proposed Recall as soon as possible and, in any event, will do so within [***] hours of
initiating a Recall. 
 5.2 Government Notices. Each party will provide the other with a copy of any correspondence or
notices it receives from the FDA, DEA or any counterpart state agency specifically relating to Services or relating to a material violation of any kind that is related to the Company or the Product, whether such violation resulted from an act or
omission by the Company or by ICS, no later than [***] business days following such receipt. In addition, ICS will provide the Company with any notice relating to Products promptly upon its receipt. Furthermore to the extent the notice is related to
the Product, Company will have right to provide input, which ICS will consider in good faith in formulating its response to the government agency. Each party will also provide the other with concurrent copies of any responses to any such
correspondence or notices (e.g., such as an FDA 483 notice, warning letters, untitled regulatory letters and establishment inspection reports). Where reasonably possible, ICS will give prior notice to the Company of any scheduled FDA or DEA
inspections of ICS’s facilities specifically relating to any Products, and, if reasonably possible, will afford the Company the opportunity to be present at such inspection and to review and contribute to any written response, to the extent
permitted by law. 
  

	6.	Legal Compliance 

 6.1
General. During the Term, each party will comply with all Requirements of Law. ICS will comply with Requirements of Law related to storage, handling and distribution of Products. The Company will comply with Requirements of Law related to
importation, manufacture, distribution, labeling, storage, sale and handling of Products. 
 6.2 Other. The Company
hereby represents and warrants to ICS that, during the Term (a) no Products delivered by or on behalf of the Company to or on the order of ICS will be, at the time of shipment or delivery, adulterated, misbranded or otherwise prohibited within
the meaning of the Act or within the meaning of any applicable state or local law, (b) all Products will be, at the time of shipment and delivery to ICS, merchandise that may be introduced and delivered into interstate commerce under the
provisions of Sections 404 or 405 of the Act, (c) all Products will be the subject of a duly approved NDA or ANDA and may be legally transported or sold under Requirements of Law, (d) all Products will have been approved by each applicable
Governmental Authority for commercial sale and shipment within the United States and (e) the Company either (i) owns or holds the duly approved Biologics License Application, as such term is used in the Public Health Service Act, Title 21,
United States Code, as amended, or the duly approved NDA or ANDA , for each of the Products, or (ii) is otherwise considered the “manufacturer” of all Products within the meaning of any applicable federal, state or local law relating
to pedigrees. 

  
 Page 4

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	7.	Representations And Warranties 

 7.1 By the Company. The Company represents and warrants to ICS that: (a) it has authority to enter into and perform this Agreement without restriction and this Agreement is a valid and binding
obligation of the Company, (b) execution, delivery and performance of this Agreement by the Company has been duly authorized by all necessary corporate actions, (c) the Company has and will maintain, in full force and effect, all licenses
and permits required under applicable law for the Company to sell and distribute Products under this Agreement, (d) as of the Program Launch Date, there is no proceeding or investigation pending or threatened that questions validity of this
Agreement, marketing authorizations related to Products or actions pursuant to this Agreement, (e) Products, or any part thereof, have not been materially adversely affected in any way as a result of any legislative or regulatory change,
revocation of the right to manufacture, distribute, handle, store, sell or market them or the Company’s breach of this Agreement, and (f) no approvals, consents, orders or authorizations of or designation, registration, declaration or
filing with any Governmental authority (within the United States) are required for Company’s performance of its obligations under this Agreement, other than any approvals already obtained. 

7.2 By ICS. ICS represents and warrants to the Company that: (a) it has authority to enter into and perform this Agreement
without restriction and this Agreement is a valid and binding obligation of ICS, (b) execution, delivery and performance of this Agreement by ICS has been duly authorized by all necessary corporate actions, (c) ICS has and will maintain in
full force and effect, all licenses and permits required under applicable law for ICS to perform the Services under this Agreement, (d) there is no proceeding or investigation pending or threatened that questions validity of this Agreement,
ICS’s licenses to warehouse and distribute pharmaceuticals, or any actions pursuant to this Agreement, (e) Products have not been materially adversely affected while in ICS’s possession as a result of any revocation of its licenses or
ICS’s breach of this Agreement, and (f) no approval of or filing with any Governmental Authority (within the United States) is required to perform Services, other than any approvals already obtained. 

7.3 Notice of Changes. The Company and ICS will give prompt written notice to the other if it becomes aware during the Term of any
action or development that would cause any warranty in this Section 7 to become untrue. 
  

	8.	Trademarks/Data 

 Neither
party may use the other party’s name, trademarks, service marks, logos, other similar marks, other intellectual property, or other data or information in any manner without its prior written approval, except to satisfy its obligations under
this Agreement. Data and information that belong to the Company will be any data and information related to Products (including sales information), except “ICS Data.” ICS Data is data and information that is not specific to Products or the
Company and was developed by ICS relating to its processes, reports and services provided to the Company under this Agreement. ICS Data, including information and data relating to any of ICS’s customers and their profiles, belongs to ICS.

  

	9.	Confidentiality 

 9.1
Existing Agreement. The parties have previously executed a written Confidentiality Agreement (“Confidentiality Agreement”), attached as Schedule E. The parties 

  
 Page 5

 
will abide by its provisions during the Term and for at least [***] years thereafter, regardless of any shorter term in the Confidentiality Agreement. Information disclosed under this Agreement
and the terms and conditions of this Agreement (including all attachments) shall be deemed “Confidential Information” under the Confidentiality Agreement. 
 9.2 Termination. Upon expiration or termination of this Agreement for any reason each party will promptly: (a) return to the other party all documents and other material containing
Confidential Information (as defined in the Confidentiality Agreement), including copies, other than those which a party is reasonably required to maintain for legal, tax or valid business purposes; or (b) certify to the other party that it has
destroyed all such documentation and other materials. 
  

	10.	Remedies 

 10.1
Generally. Rights and remedies under this Agreement are cumulative and in addition to any other available rights or remedies under any agreement, at law or in equity. 
 10.2 Equitable Relief. If either party violates or threatens to violate Recall, Legal Compliance, Trademark/Data infringement, Confidentiality or other provisions of this Agreement, the other party
may suffer irreparable harm and its remedies at law may be inadequate. Accordingly, the other party may seek equitable relief. 

10.3 Breach by the Company. The Company acknowledges the difficulty (if not the impossibility) of ascertaining the amount of
damages that would be suffered by ICS if (i) the Company terminates this Agreement without cause or (ii) ICS terminates this Agreement following a breach by the Company. In such event, as compensation and not as a penalty, the early termination fee
(the “ETF”) payable to ICS shall be equal to [***] of the aggregate amount of all fees and other sums that, in absence of such breach, would have been paid by the Company to ICS under this Agreement for the remaining months of the Term,
with such fees and other sums to be based on the average monthly amount paid or owed by the Company to ICS during the [***] months preceding such breach (or such shorter time as the Agreement has been in effect). The ETF is in addition to any other
claims or amounts owed by Company to ICS under this Agreement, including Fees for Services performed and costs incurred prior to the effective date of termination and indemnification obligations under this Agreement and the Continuing Guaranty and
Indemnification Agreement referenced in Section 13 below (the “Continuing Guaranty”). 
 10.4
LIMITATIONS. EXCEPT FOR EACH PARTY’S OBLIGATIONS OF CONFIDENTIALITY UNDER SECTION 9, INDEMNIFICATION UNDER SECTIONS 11.1 AND 11.2, AND INTELLECTUAL PROPERTY UNDER SECTION 12: 

(A) EXCEPT FOR ANY LIABILITY UNDER SECTION 10.3 ABOVE, NO PARTY WILL BE LIABLE TO ANY OTHER PARTY FOR ANY CONSEQUENTIAL, INCIDENTAL,
INDIRECT, SPECIAL OR OTHER SIMILAR DAMAGES ARISING OUT OF OR IN CONNECTION WITH A BREACH OF THIS AGREEMENT; 
 (B) ANY
LOSS DUE TO DAMAGE OR LOSS OF PRODUCTS WILL BE BASED UPON THE COMPANY'S COST OF MANUFACTURING OR ACQUIRING PRODUCTS, NOT ITS SELLING COST; AND 
 (C) COMPANY UNDERSTANDS AND AGREES THAT IT HOLDS TITLE AND RISK OF LOSS FOR THE PRODUCTS AT THE ICS FACILITY UNDER THIS AGREEMENT. AS A SERVICE PROVICER, ICS DOES NOT ACCEPT LIABILITY FOR DAMAGE OR
LOSS 

  
 Page 6

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
TO THE PRODUCT WHILE IN THE ICS FACILITY, EXCEPT FOR LIABILITY FOR THIRD PARTY CLAIMS SUBJECT TO INDEMNIFICATION UNDER SECTION 11.2 BELOW. NOTWITHSTANDING THE FOREGOING, ICS AGREES THAT IF DAMAGE
OR LOSS TO PRODUCTS IS CAUSED BY: (1) A BREACH OF THIS AGREEMENT BY ICS, ICS SHALL BE LIABLE FOR SUCH LOSS UP TO A MAXIMUM AMOUNT EQUAL TO THE ETF (AS DEFINED UNDER SECTION 10.3(C) ABOVE); OR (2) ICS’S GROSSLY NEGLIGENT OR WILLFUL ACT
OR OMISSION, THEN NO LIMITATION OF LIABILITY SHALL APPLY, EXCEPT FOR THE LIMITATIONS OF SECTIONS 10.4(A) AND (B) ABOVE. COMPANY IS RESPONSIBLE FOR ENSURING THAT IT HAS APPROPRIATE INSURANCE IN PLACE TO PROTECT ITSELF FROM POTENTIAL DAMAGE OR
LOSS TO ITS PRODUCTS. THE INSURANCE REQUIRED UNDER SECTION 13 BELOW IS A MINIMUM ONLY, AND ICS DOES NOT REPRESENT OR WARRANT THAT THESE COVERAGES ARE SUFFICIENT FOR COMPANY’S NEEDS. 

 

	11.	Indemnification 

 11.1
By the Company. The Company will defend, indemnify and hold harmless ICS and its Related Parties from and against all claims, liabilities, losses, damages, costs and expenses, including reasonable attorneys’ fees (collectively,
“Claims”) brought by third parties or the Company’s employees caused by or arising from any (a) negligent act or omission of the Company or its Related Parties, (b) failure of the Company to perform its obligations or to
comply with Requirements of Law, (c) breach of any warranty made by the Company in this Agreement (d) claims of patent, trademark, copyright or other infringement related to Products, (e) storage, handling, use, non-use,
demonstration, consumption, ingestion, digestion, manufacture, production and assembly of Products and their transportation to ICS, or (f) Taxes imposed against ICS or its Related Parties; provided, however, the Company will have no
obligations under this Section 11.1 for any Claims to the extent caused by any negligent act or omission of ICS or its Related Parties. 
 11.2 By ICS. ICS will defend, indemnify and hold harmless the Company and its Related Parties from and against all Claims brought by third parties or ICS’s employees against the Company or its
Related Parties caused by or arising from any (a) negligent act or omission of ICS or its Related Parties, (b) failure of ICS to perform its obligations or to comply with Requirements of Law, (c) breach of any warranty made by ICS in
this Agreement, or (d) making by ICS of representations or warranties with respect to Products to the extent not authorized by the Company; provided, however, that ICS will have no obligations under this Section 11.2 for any Claims
to the extent caused by any negligent act or omission of the Company or its Related Parties. 
 11.3 Procedures. The
obligations and liabilities of the parties with respect to Claims subject to indemnification under this Section 11 (“Indemnified Claims”) will be subject to the following terms and conditions: 

11.3.1 The party claiming a right to indemnification hereunder (“Indemnified Person”) will give prompt written notice to the
indemnifying party (“Indemnifying Person”) of any Indemnified Claim, stating its nature, basis and amount, to the extent known. Each such notice will be accompanied by copies of all relevant documentation, including any summons, complaint
or other pleading that may have been served or any written demand or other document. 
 11.3.2 With respect to any Indemnified
Claim: (a) the Indemnifying Person will defend or settle the Indemnified Claim, subject to provisions of this subsection, (b) the Indemnified Person will, at the Indemnifying Person’s sole cost and expense, cooperate in the

  
 Page 7

 
defense by providing access to witnesses and evidence available to it, (c) the Indemnified Person will have the right to participate in any defense at its own cost and expense to the extent
that, in its judgment, the Indemnified Person may otherwise be prejudiced thereby, (d) the Indemnified Person will not settle, offer to settle or admit liability in any Indemnified Claim without the written consent of an officer of the
Indemnifying Person, and (e) the Indemnifying Person will not settle, offer to settle or admit liability as to any Indemnified Claim in which it controls the defense if such settlement, offer or admission contains any admission of fault or
guilt on the part of the Indemnified Person, or would impose any liability or other restriction or encumbrance on the Indemnified Person, without the written consent of an officer of the Indemnified Person. 

11.3.3 Each party will cooperate with, and comply with all reasonable requests of, each other party and act in a reasonable and good
faith manner to minimize the scope of any Indemnified Claim. 
  

	12.	Intellectual Property 

All concepts, inventions, ideas, patent rights, data, trademarks, and copyrights that are related to Products will remain exclusive
property of the Company, except those not specific to Products and that relate to the general processes, reports and services developed by ICS and provided to the Company. Any concepts, inventions, ideas, patent rights, data, trademarks, and
copyrights that are developed by ICS that are not specific to Products or that relate to the processes, reports and services developed by ICS will remain the exclusive property of ICS. 

 

	13.	Insurance 

 13.1 By the
Company. Within [***] days prior to product launch and for the remainder of the Term, the Company will maintain: (a) casualty and theft or loss insurance in amounts sufficient to protect all Products and other materials consigned to ICS,
and (b) products liability and commercial general liability insurance having a limit of not less than [***] per occurrence, Combined Single Limit (Bodily Injury and Property Damage), pursuant to one or more insurance policies with reputable
insurance carriers having a Best’s Rating of A VII or otherwise as reasonably approved by ICS. The Company will designate ICS and its Related Parties as “additional insureds” under each such insurance policy. The Company will obtain a
broad form vendor’s endorsement for products liability for ICS and its Related Parties. Within [***] days prior to product launch, the Company will provide to ICS a certificate of insurance indicating that such obligations have been satisfied.
As a condition precedent to the effectiveness of this Agreement, the Company will execute the form of Continuing Guaranty and Indemnification Agreement attached as Exhibit A. 

13.2 By ICS. During the Term, ICS will maintain the following insurance: 

13.2.1 Workers’ Compensation. Workers’ compensation statutory coverage as required by law in states where Services are
performed; 
 13.2.2 Employer’s Liability. Employer’s liability insurance with a limit of [***] for bodily injury by
accident per person, [***] for bodily injury by accident, all persons and [***] bodily injury by disease policy limit; 
 13.2.3
General Liability. Commercial general liability insurance, including personal injury blanket contractual liability and broad form property damage, with a [***] combined single limit; 

  
 Page 8

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 13.2.4 Umbrella Liability. Umbrella liability insurance in the amount of [***] per
occurrence and aggregate; 
 13.2.5 Property Insurance. Property insurance covering the business property of ICS and others
while at any unnamed location in the amount of [***]; and 
 13.2.6 Other. ICS will not be obligated to insure Products against
any loss or damage to Products arising from the shipment or storage of Products at the ICS Facility. 
 13.3
Self-Insurance, The insurance required by Section 13 may be made up through a combination of self-insured retention and traditional insurance. 
 13.4 Source of Recovery. Except to the extent that ICS is liable for Product damage or loss under Section 10.4(c) above, the Company agrees to look for recovery in respect of
any such loss or damage solely to the casualty and theft or loss insurance provided by the Company in accordance with Section 13.1 of this Agreement. 
 13.5 Notice and Proof of Insurance. Throughout the Term, ICS will (a) provide prompt written notice to the Company in the event ICS becomes aware or is notified that the insurance described in
Section 13.2 will be materially adversely modified or cancelled and (b) provide the Company with proof of such insurance. 
  

	14.	Notices 

 Notices will be
in writing and will be delivered personally (which will include delivery by courier or reputable overnight delivery service) or sent by certified mail, postage and fee prepaid, return receipt requested, to the address on the signature page. Items
delivered personally will be deemed delivered on the date of actual delivery. Items sent by certified mail will be deemed delivered on the date the return receipt is signed. A party may change its contact information by a written notice delivered in
accordance with this Section 14. 
  

	15.	Governing Law 

 This
Agreement and the rights and obligations of the parties under this Agreement will be construed and interpreted under the internal laws of the State of Texas, excluding its conflict and choice of law principles. The successful party in any legal
action arising out of this Agreement, including enforcing its rights in a bankruptcy proceeding, may recover all costs, including reasonable attorneys’ fees. 
  

	16.	Severability 

 If any
court determines a provision of this Agreement is invalid, such holding will not affect the validity of other provisions and they will remain in effect. 
  

	17.	Complete Agreement; Amendments; Counterparts; Waivers; Signatures. 

 This Agreement and its schedules and exhibits, including the Confidentiality Agreement and Continuing Guaranty, contain the entire agreement between the parties and supersede any prior oral and written
representations by the parties that relate to the subject matter of this Agreement. This Agreement may not be amended, supplemented or waived in any respect without written agreement of both parties, signed by their respective authorized
representatives. This Agreement may be executed in one or more counterparts, which will together constitute but one agreement and each of which will be an original. A party’s failure to insist, in one or more instances, upon performance of any
provision of this Agreement will not be construed as a 

  
 Page 9

 
waiver of its right and the other party’s obligations will continue in full force. Either party’s consent to any act by the other party on any occasion will not be deemed consent on any
other occasion. Facsimile transmissions bearing a party’s signature will for all purposes be deemed an original. 
  

	18.	Force Majeure 

 If the
performance of any part of this Agreement by any party will be affected for any length of time by fire or other casualty, government restrictions, war, terrorism, riots, strikes or labor disputes, lock out, transportation delays, electronic
disruptions, internet, telecommunication or electrical system failures or interruptions, and acts of God, or any other cause which is beyond control of a party (financial inability excepted), such party will not be responsible for delay or failure
of performance of this Agreement for such length of time, provided, however, (a) the affected party will cooperate with and comply with all reasonable requests of the non-affected party to facilitate Services to the extent possible, and
(b) the obligation of one party to pay amounts due to any other party will not be subject to the provisions of this Section. 
  

	19.	Interpretation 

 Each
party to this Agreement (i) has participated in the preparation of this Agreement, (ii) has read and understands this Agreement, and (iii) has been represented by counsel of its own choice in the negotiation and preparation of this
Agreement. Each party represents that this Agreement is executed voluntarily and should not be construed against a party solely because it drafted all or a portion of this Agreement. Headings of the various Sections are not part of the context of
this Agreement, and are only labels to assist in locating those Sections, and will be ignored in construing this Agreement. When this Agreement requires approval of one or more parties, such approval may not be unreasonably withheld or delayed.
Words, regardless of the number and gender specifically used, will be construed to include any other number, singular or plural, and any gender, masculine, feminine, or neuter, as the context requires. “And” includes “or.”
“Or” is disjunctive but not necessarily exclusive. “Including” means “including but not limited to.” 
  

	20.	Successors 

 The Company
may not assign this Agreement or any of its rights or obligations without ICS’s prior written consent. Upon consent, this Agreement will be binding upon the successor party. Such consent shall not be unreasonably withheld. 

 

	21.	Relationship Of The Parties 

 Neither party has any ownership interest in the other and their relationship, as established by this Agreement, is that of agent and master within the confines of the terms of this Agreement. Other than
such limited agency, this Agreement does not create any partnership, joint venture or similar business relationship between the parties. Notwithstanding the limited agency created hereunder, each party will remain fully responsible for its actions
and the actions of its Related Parties not specifically related to this Agreement. 
 22. Implementation Costs. Upon execution
of this Agreement by the Company, the Company shall pay ICS half of the Implementation Fee on Schedule B ([***]). The Company shall pay the remaining half of the Implementation Fee [***] to ICS on the date on which ICS provides notice that it has
achieved launch-ready status. 

  
 Page 10

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the parties have had a duly authorized officer, partner or principal
execute this Commercial Outsourcing Services Agreement as of the Effective Date. 
  

									
	 COMPANY: Corcept Therapeutics
  
	 		 	INTEGRATED COMMERCIALIZATION SOLUTIONS, INC.
					
	By:	 	 /s/ Joseph K. Belanoff
	 		 	By:	 	 /s/ Doug Cook

					
	Name:	 	 Joseph K. Belanoff
	 		 	Name:	 	 Doug Cook

					
	Title:	 	 CEO
	 		 	Title:	 	 VP, General Manager

					
	Address:	 	 149 Commonwealth Drive

Menlo Park, CA 9402
  
	 		 	Address:	 	 Attn: Executive Vice President and
 General Manager
 3101 Gaylord Parkway
 Frisco, TX 75034

		 		 		 		 	  
 with a copy to:

 
 AmerisourceBergen Specialty Group, Inc.

Attn: Group Counsel, 1N-E186
 3101 Gaylord
Parkway
 Frisco, TX 75034

		 		 		 		 

  

					
	 Program Launch Date: December 31, 2011
	  		  	
	[If blank, the Program Launch Date will be 60 days after the Effective Date]	  	 

  
 Page 11

 LIST OF SCHEDULES AND EXHIBITS 

[Note: This list is to be revised in accordance with the actual Schedules and Exhibits used for each client agreement.] 

 

			
	Schedules:	  	
		
	Schedule A	  	Description of Products
	Schedule B	  	Summary of Fees
	Schedule C	  	Additional Definitions
	Schedule D	  	Example of Price Adjustment Calculation
	Schedule E	  	Copy of Executed Confidentiality Agreement
		
	Exhibits:	  	
		
	Exhibit A	  	Continuing Guaranty and Indemnification Agreement
	Exhibit B	  	Customer Services
	Exhibit C	  	Warehousing and Inventory Program Services
	Exhibit D	  	Distribution Services
	Exhibit E	  	Warehousing and Distribution of Sample Products
	Exhibit F	  	Marketing Materials Fulfillment Services
	Exhibit G	  	Contract Administration and Chargeback Processing
	Exhibit H	  	Accounts Receivable Management and Cash Applications
	Exhibit I	  	Financial Management Services
	Exhibit J	  	IT Services

  
 Page 12

 SCHEDULE A 
 DESCRIPTION OF PRODUCTS 
  

			
	 Description
	  	 NDC Number

		
	Corlux	  	TBD
		
	Samples	  	
		
	Free Goods	  	

  
 Page 13

 SCHEDULE B 
 SUMMARY OF FEES 
  

					
	 Fee
	 	 Amount
	  	 Description

	
	3PL Services
			
	Development and Implementation	 	[***]	  	 •   Hiring and training of staff

 
 •   ERP system set
up
  

•   Project management time for implementation

 
 •   Data
interface design and testing **Should data file transfer custom development be required, additional fees will apply at the per hour rate
  

•   Corcept-specific telecommunications set up

 
 •   Creation of a
Corcept-specific DataMart and RealTime Web Portal
  
 •   852/867 Service Support set up
  

•   If a website is developed for ordering marketing materials, there will be an additional
one-time fee of $10,000

			
	Stand-Ready Fee	 	[***]month	  	Monthly fee assessed if Program Launch Date is delayed.
	
	Monthly Management Fee
			
	Customer Service	 	[***]	  	 •   Address customer inquiries as Corcept

			
	Warehouse & Distribution	 		  	 •   Manage Customer Relationship

			
	Returns Management	 	[***]	  	 •   Account Set Up

			
	Finance	 	[***]	  	 •   License Verification

			
	  
 Information Technology & Reporting

 
 Chargeback Management

 
 Sample Management

 
 Marketing Material Management
	 	[***]	  	 •   Order Processing

 
 •   Sample Order
Processing
  

•   Marketing Material Order Processing

 
 •   Returns

 
 •   Product
Inquiries
  

•   Inventory pick, pack and ship from ICS distribution center

 
 •   Corcept-Branded
Packing Slips
  

•   Daily Cycle Counts

 
 •   One Physical
Inventory Count per annum
  

•   Inventory Management

 
 •   Invoicing as
Corcept
  

•   Establish Credit Limits

 
 •   Process
Returns
  

•   Call Triage

 
 •   Accounts Receivable
Management
  

•   Collections

  
 Page 14

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	 Fee
	 	 Amount
	  	 Description

			
		 		  	 •   Debit memo processing

 
 •   Reconciliation
reporting
  

•   Chargeback processing and System Maintenance

 
 •   Maintenance of
Corcept specific DataMart and web reporting tool
  
 •   Maintenance of Business Objects for web reporting
  

•   Future upgrades to ICS’ software

 
 •   Includes two
licenses to Business Objects reporting tool

	 Customer Service Fees

			
	Order Processing Fee	 	 [***]
  

[***]
  

[***]
	  	 Order is defined as a shipment to a unique address that leaves the distribution center, regardless of the number of cartons or packages
that constitute that shipment and/or the number of inbound requests for said Order.
  
 Electronic orders are those that are imported into the system automatically without manual intervention from customer service.

			
	Customer Setup Fee	 	[***]	  	Assessed for every new account setup completed for an authorized Corcept customer. This includes license receipt and verification after initial launch setup.
			
	Account Maintenance/ License Updates	 	[***]	  	Fee to perform any type of account update or to update license on account.
			
	Drop Shipment Surcharge	 	[***]	  	Assessed in addition to Per Order fees outlined above, when drop shipments are requested. Drop Shipments are defined as shipments that are shipped directly to an end customer of the
wholesaler, and invoiced directly to the wholesaler.
			
	Allocation Fee	 	[***]	  	Order allocations encompass any inbound orders to ICS that needs to have original conditions revised and/or altered (i.e. manual intervention) as opposed to allowing the order to
automatically flow through the order process system. An example of an allocation would be a backorder situation.
			
	Rush Order	 	[***]	  	Orders that are received and processed between 3:00 p.m. and 5:00 p.m. ET, at the request of the Corcept.
			
	Emergency Order	 	[***]	  	Emergency shipments are defined as any order received outside of scheduled working hours (currently M-F 8:00 a.m. to 5:00 p.m. ET) requiring ICS staff to return to the ICS facility
to process the order within the same day.
			
	International Order	 	[***]	  	Fee applied in addition to any order processing fees.

  
 Page 15

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	 Fee
	 	 Amount
	  	 Description

	
	Warehouse & Distribution Fees
			
	Product Storage	 	[***]	  	Monthly fee for controlled temperature pallet storage.
			
	 Order Processing Fees
  

Ambient Trade Product
	 	 [***]
 [***]
  
 [***]
  
 [***]
  
 [***]
  
 [***]
  
	  	 Order is defined as a shipment to a unique address that leaves the distribution center, regardless of the number of cartons or packages
that constitute that shipment and/or the number of inbound requests for said Order.
  
 Line is defined as each SKU or product line picked on the order.
 Unit is defined as each unit of
measure picked on the order.

			
	 Sample/Marketing Distribution
  

Ambient
	 	 [***]
  

[***]
  

[***]
	  	 Order is defined as a shipment to a unique address that leaves the distribution center, regardless of the number of cartons or packages
that constitute that shipment and/or the number of inbound requests for said Order.
  
 Line is defined as each SKU or product line picked on the order.
 Pick is defined as each unit of
measure picked on the order.

			
	Receiving Fee	 	[***]	  	Fee assessed each pallet received into the warehouse.
			
	Shipping Fee	 	[***]	  	Fee assessed each pallet shipped from the warehouse.
			
	Bulk Shipments	 	[***]	  	Fee for LTL shipments; replaces smaller shipper fees below.
			
	Packing Supplies	 	[***]	  	Any packing materials that ICS must provide for the Corcept to ship Commercial and Non-Commercial Products.
			
	Freight	 	[***]	  	ICS will share AmerisourceBergen Corporation (ABC) discounted rates with Corcept with a mark-up of 10%.
	
	Finance
			
	Invoice Processing	 	[***]	  	Fee for sending invoice (electronic or paper) to customer, collection efforts and cash posting.
			
	Credit/Rebill Transactions	 	[***]	  	Any Corcept requested credit or rebill transactions keyed in the system.
			
	Credit Verification Reports – Dun & Bradstreet	 	[***]	  	Any Corcept requested credit report. Dun & Bradstreet (D&B) typically tracks information for corporate customers.
			
	Credit Verification Reports – Experian	 	[***]	  	Any Corcept requested credit report. Experian typically tracks information for individual customers such as
physicians.

  
 Page 16

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	 Fee
	 	 Amount
	  	 Description

	
	Returns Management
			
	RGA Initiation	 	 [***]
  

[***]
	  	 RGA: Returned Goods Authorization.
  

Fee for processing return request from customer and sending the customer an RGA.

			
	Return Processing	 	[***]	  	Receipt of physical return at the distribution center. Fee includes itemizing contents of the return
			
	Partial Return Processing	 	[***]	  	Fee applied in addition to Return Processing fee for handling and counting partial containers.
			
	Returns Storage	 	[***]	  	Monthly fee for controlled room temperature pallet storage.
	
	Contract and Chargeback Management
			
	Chargeback Processing – Manual	 	[***]	  	Each SKU is considered a line. If customers cannot send information electronically, they will mail information for manual processing. ICS and Customer must have copies of
contracts in order to process chargebacks without manual intervention.
			
	Chargeback Processing – Electronic	 	[***]	  	Each SKU is considered a line. Customers will typically send chargebacks electronically according to HDMA standards.
			
	Membership Additions	 	[***]	  	Fee to add members to an account.
			
	Contract Setup	 	[***]	  	Fee to add new contract to client account.
			
	Contract Updates	 	[***]	  	Fee assessed any time an account requires a change or update to an existing contract.
	
	Information Technology and Reporting
			
	852/867: ABC, CAH, MCK	 	[***]	  	Maintenance and mapping of the 852 and 867 reporting.
			
	Custom Reports	 	[***]	  	Fee for reports created that are not part of the standard reports provided by ICS. Hourly report creation fees assessed for initial report creation but not thereafter for running
the same report.
			
	Custom Development Services	 	[***]	  	Fee for customized processes developed at the request of Corcept. Hourly fees will be assessed and approved by Corcept before development work is to begin.
	
	Additional Fees
			
	Product Destruction	 	[***]	  	Destruction of product per Corcept request and instruction.
			
	FedEx/UPS/Postage Expenses	 	[***]	  	Freight expenses for shipments of documents or any other shipments related to daily operations on behalf of
Corcept.

  
 Page 17

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	 Fee
	 	 Amount
	  	 Description

			
	Pre-Approved Assessorial Labor Charge – Warehouse	 	[***]	  	This fee will be assessed for work that is completed outside the scope of the agreed upon services outlined in the Services Agreement. Corcept must provide prior approval before
assessorial labor takes place.
			
	Pre-Approved Assessorial Labor Charge – Office Staff	 	[***]	  	This fee will be assessed for work that is completed outside the scope of the agreed upon services outlined in the Services Agreement. Corcept must provide prior approval before
assessorial labor takes place.
			
	Pre-Approved Assessorial Labor Charge – QC, Management	 	[***]	  	This fee will be assessed for work that is completed outside the scope of the agreed upon services outlined in the Services Agreement. Corcept must provide prior approval before
assessorial labor takes place.
			
	ICS Travel	 	[***]	  	This is for Corcept requested travel. Corcept must provide prior approval before travel takes place.

  
 Page 18

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 SCHEDULE C 
 ADDITIONAL DEFINITIONS 
 “Act” means the Federal Food, Drug and Cosmetic
Act, Title 21, United States Code, as amended, and the regulations promulgated thereunder. 
 “ANDA” means an Abbreviated New
Drug Application as defined in and contemplated by the Act. 
 “Customer” is defined in Agreement Section 1. 

“DEA” means the United States Drug Enforcement Administration. 
 “FDA” means the United States Food and Drug Administration. 

“Governmental Authority” means any nation, government, state or other political subdivision, or any entity exercising executive,
legislative, judicial, regulatory or administrative functions of or pertaining to government. 
 “ICS Facility” means the
facility located at 420 International Blvd. Suite#500, Brooks, KY 40109 or 5360 Capital Court #102, Reno, NV 89502. 
 “NDA”
means a New Drug Application as defined in and contemplated by the Act. 
 “Person” means any corporation, natural person, the
Company, entity, firm, joint venture, partnership, trust, unincorporated organization, or Government Authority. 
 “Products”
is defined in Agreement Recital A. 
 “Related Parties” means the subsidiaries, parents, affiliated companies, officers,
directors, employees, independent contractors, representatives, shareholders, trustees and agents of any Person. 
 “Requirements of
Law” means any law (including consumer law), treaty, rule or regulation or a final and binding determination of a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to
which such Person or any of its property is subject. 
 “Services” is defined in Agreement Section 2.1. 

“Taxes” means any and all liabilities, losses, expenses, and costs of any kind whatsoever that are, or are in the nature of taxes, fees,
assessments, or other governmental charges, including interest, penalties, fines and additions to tax imposed by any federal, state or local government or taxing authority in the United States on or with respect to: (a) the Agreement or any
related agreements or any future amendment, supplement, waiver, or consent requested by the Company or any required by the Agreement with respect to the execution, delivery or performance of any thereof, or the issuance, acquisition or subsequent
transfer thereof, (b) the return, acquisition, transfer of title, storage, removal, replacement, substitution, purchase, acceptance, possession, rejection, ownership, delivery, non-delivery, use, operation, sale, abandonment, redelivery or
other disposition of any interest in Products or any part thereof, (c) the receipts or earnings arising from any interest in Products or any part thereof, (d) any 

  
 Page 19

 
payment made pursuant to this Agreement or to any Products, or (e) otherwise as a result of or by reason of the transactions contemplated by this Agreement, excluding, however, taxes imposed
upon ICS that are based upon or measured by gross or net income and any franchise Taxes of ICS or any personal property taxes for Products or equipment owned by ICS. 
 “Term” is defined in Agreement Section 4.1. 

  
 Page 20

 SCHEDULE D 
 COPY OF EXECUTED CONFIDENTIALITY AGREEMENT 
 MUTUAL NON-DISCLOSURE AGREEMENT

 This Mutual Non-Disclosure Agreement is made as of March 22, 2011 (“the Effective Date) between AmerisourceBergen
Specialty Group, Inc., with offices at 3101 Gaylord Parkway, Frisco, TX 75034 and Corcept Therapeutics, Inc., with offices at 149 Commonwealth Drive, Menlo Park, CA 94025. 
 Background 
 The parties are interested in evaluating a potential
venture relating to warehousing, distribution and other commercial services (the “Venture”). In order to facilitate such evaluation, either party (“Disclosing Party”) may disclose to the other party (“Recipient”)
certain of its confidential or proprietary information. 
 1. Definition of Confidential Information. “Confidential
Information” means any confidential or proprietary information that is disclosed or made available by Disclosing Party to Recipient, whether in writing or other tangible form, orally or otherwise. Confidential Information includes
(a) information about processes, systems, strategic plans, business plans, operating data, financial information and other information and (b) any analysis, compilation, study or other material prepared by Recipient (regardless of the form
in which it is maintained) that contains or otherwise reflects any information disclosed or made available by Disclosing Party to Recipient. 
 2. Exclusions from Confidential Information. Confidential Information does not include information that: 
 (a) at the time of disclosure to Recipient, is generally available to the public; 

(b) after disclosure to Recipient, becomes generally available to the public other than as a result of a breach of these provisions by
Recipient (including any of its affiliates); 
 (c) Recipient can establish was already in its possession at the time the
information was received from Disclosing Party if its source was not known by Recipient to be bound to an obligation of confidentiality with respect to such information; 
 (d) Recipient receives from a third party if its source was not known by Recipient to be bound to an obligation of confidentiality with respect to such information; or 

(e) Recipient can establish was developed independently by Recipient without use, directly or indirectly, of any Confidential
Information. 
 3. Limitations on Disclosure and Use. Confidential Information must be kept strictly confidential and may
not be disclosed or used by Recipient except as specifically permitted by this Agreement or as specifically authorized in advance in writing by Disclosing Party. Recipient may not take any action that causes Confidential Information to lose its
confidential and proprietary nature or fail to take any reasonable action necessary to prevent any Confidential Information from losing its confidential and proprietary nature. Recipient will limit access to Confidential Information to its
employees, officers, directors or other authorized representatives (or those of its affiliates) who (a) need to know such Confidential Information to participate in evaluating the Venture and (b) are obligated to

  
 Page 21

 
Recipient to maintain Confidential Information under terms and conditions at least as stringent as those under this Agreement. Recipient will inform all such persons of the confidential and
proprietary nature of Confidential Information and will take all reasonable steps to ensure they do not breach their confidentiality obligations, including taking any steps Recipient would take to protect its own similarly confidential information.
Recipient will be responsible for any breach of confidentiality obligations by such persons. 
 4. Ownership. All
Confidential Information and deviations of Confidential Information will remain the sole and exclusive property of Disclosing Party and, except as provided, no license or other right to it will be implied by this Agreement. If Recipient has prepared
any analysis, compilation, study or other material (regardless of form) that contains or otherwise reflects any Confidential Information, then such material will be owned solely by Disclosing Party and treated as its Confidential Information under
this Agreement. 
 5. No Representations or Warranties. Recipient acknowledges that Disclosing Party makes no
representations of warranties, express or implied, as to the accuracy or completeness of Confidential Information and Recipient agrees that Disclosing Party will have no liability for any errors or omissions in such information. 

6. Return or Destruction of Confidential Information. Upon Disclosing Party’s request, Recipient will promptly deliver to
Disclosing Party or destroy all Confidential Information (including material that contains or otherwise reflects Confidential Information) in its custody or control and will deliver it to Disclosing Party within ten (10) business days after
such request or deliver a written statement from a corporate officer certifying it has destroyed all of Disclosing Party’s Confidential Information. Unless authorized in writing by Disclosing Party Recipient will not retain any copy, extract or
summary of Confidential Information (including material that contains or otherwise reflects Confidential Information). The obligation to destroy or return shall not apply to Confidential Information that is stored on back-up tapes and similar media
that are not readily accessible to Recipient. 
 7. Equitable Relief. Each party acknowledges that, when it is Recipient,
money damages would not be a sufficient remedy for Disclosing Party in the event of any breach of these provisions and that Disclosing Party is entitled to seek specific performance and injunctive or other equitable relief as a remedy for any such
breach. Recipient further agrees to waive any requirement for the posting of any bond in connection with any such remedy. Such remedy will be in addition to any other available remedies at law or in equity. 

8. Disclosures Required by Law. If Recipient is required by law to disclose any Confidential Information, Recipient will give
Disclosing Party prompt notice and will use all reasonable means to obtain confidential treatment for any Confidential Information that it is required disclose before making any such disclosure. If Recipient cannot assure confidential treatment and
it has exhausted all reasonable efforts to do so, Recipient may disclose Confidential Information to the extent it is required by law to disclose the information it discloses. Notwithstanding the foregoing, Disclosing Party may request Recipient to
take additional steps to seek confidential treatment before Recipient discloses Confidential Information even though Recipient has otherwise exhausted all reasonable efforts to do so. In such event, Recipient will undertake such additional steps at
Disclosing Party’s expense. 
 9. Term of this Agreement. This Agreement covers Confidential Information that is
disclosed by Disclosing Party to Recipient until the first anniversary of the Effective Date. Recipient’s obligation to protect Confidential Information disclosed during such one-year period expires three years from the Effective Date.

  
 Page 22

 10. Subsequent Agreement. If the patties pursue the Venture, they anticipate entering
into a definitive agreement that will set forth their respective obligations. Such agreement may incorporate this Agreement by reference, may supplement or modify it or may supersede it. 

11. Governing Law; Jurisdiction; Attorneys’ Fees. Internal law of the State of Texas applies to this Agreement. Each of the
parties agrees that any legal or equitable action relating to this Agreement shall be brought, and each of the parties consents to personal jurlsdictlon1 in any court of general jurisdiction in Collin County, Texas, and waives any objection which it
may have to the laying of venue of any such suit, action or proceeding in such court. The successful party in any legal action arising our of this Agreement may recover all costs, including reasonable attorneys’ fees. 

12. Notices. Any notice required or permitted under this Agreement will be in writing and will be effective upon actual receipt.
Notices shall be sent to the addresses set forth in the introductory paragraph of this Agreement, and a copy of any notice to AmerisourceBergen Specialty Group, Inc. shall also be sent to AmerisourceBergen Specially Group, Inc., Attn: Group Counsel,
lN-El86, 3101 Gaylord Parkway, Frisco, TX 75034. 
 13. Interpretation. This Agreement is the entire agreement between
the parties with respect to its subject matter and supersedes any prior agreement, written or oral. This Agreement will bind and benefit the parties and their successors. This Agreement may be assigned by AmerisourceBergen Specialty Group, Inc. to
any affiliate hut may not be otherwise assigned without the consent of the other party, which consent will not be unreasonably withheld. For purposes of Agreement, “affiliate” means any company or person that directly or indirectly
controls, is controlled by or under common control with the referenced party, as the case may be. If any provision is invalid, validity of remaining provisions will not be affected. This Agreement may not be amended or modified except in a writing
signed by both paties. Any waiver or delay by any party in enforcing this Agreement will not deprive it of the right to take appropriate action at a later time or due to another breach. Captions in this Agreement are intended for convenience of
reference only. Words, regardless of the number and gender specifically used, will be construed to include any other number, singular or plural, and any gender, masculine, feminine, or neuter, as the context requires. “And” includes
“or.” “Or” is disjunctive but not necessarily exclusive. “Including” means “including but not limited to.” This Agreement may be executed in counterparts. Any provision of this Agreement may survive this
Agreement’s expiration or earlier termination if its context shows that the parties intended it to survive. 
 IN WITNESS
WHEREOF, the parties have executed this Mutual Non-Disclosure Agreement as of its Effective Date. 
  

											
	 	 	AmerisourceBergen Specialty Group, Inc.	 	Corcept Therapeutics, Inc.
						
		 	By:	 	 /s/ James D. Frary
	 		 	By:	 	 /s/ Joseph K. Belanoff

						
		 	Title:	 	 James Frary
	 		 	Title:	 	 Joseph K. Belanoff, M.D.

						
		 	Title:	 	 President, ABSG
	 		 	Title:	 	 Chief Executive Officer

  
 Page 23

  
 

 
 EXHIBIT A 
 CONTINUING GUARANTY AND INDEMNIFICATION AGREEMENT 
 The undersigned does hereby guarantee
to AmerisourceBergen Corporation and each of its subsidiary companies and their successors that any food, drugs, devices, cosmetics, or other merchandise (“Products”) now or hereafter shipped or delivered by or on behalf of the
undersigned, its subsidiaries, divisions, affiliated companies and representatives (“Guarantors”) to or on the order of AmerisourceBergen Corporation or any of its subsidiaries will not be, at the time such shipment or delivery,
adulterated, misbranded, or otherwise prohibited under applicable federal, state and local laws, including applicable provisions of the Federal Food, Drug and Cosmetic Act, 21 U.S.C.A. §301 et seq., (“FDCA”), and Sections 351 and 361
of the Federal Public Health Service Act, 42 U.S.C.A. §§ 262 and 264, and their implementing regulations (“Applicable Laws”), each as amended and in effect at the time of shipment or delivery of such Products; and such Products
are not, at the time of such shipment or delivery, merchandise which may not otherwise be introduced or delivered for introduction into interstate commerce under Applicable Laws, including FDCA section 301 (21 U.S.C.A. §331); and such Products
are merchandise which may be legally transported or sold under the provisions of any other applicable federal, state or local law; and Guarantors guarantee further that, in the case of food shipments, only those chemicals or sprays approved by
federal, state or local authorities have been used, and any residue in excess of the amount allowed by any such authorities has been removed from such Products. 
 Guarantors hereby agree to defend, indemnify and hold AmerisourceBergen Corporation and each of its subsidiaries harmless against any and all claims, losses, damages, and liabilities whatsoever (and
expenses connected therewith, including counsel fees), arising as a result of (a) any actual or asserted violation of Applicable Laws or by virtue of which Products made, sold, supplied, or delivered by or on behalf of Guarantors may be alleged
or determined to be adulterated, misbranded or otherwise not in full compliance with or in contravention of Applicable Laws, (b) possession, distribution, sale and/or use of, or by reason of the seizure of, any Products of Guarantors, including
any prosecution or action whatsoever by any governmental body or agency or by any private party, including claims of bodily injury, death or property damage, (c) any actual or asserted claim that Guarantors’ Products infringe any
proprietary or intellectual property rights of any person, including infringement of any trademarks or service names, trade names, trade secrets, inventions, patents or violation of any copyright laws or any other applicable federal, state or local
laws, and (d) any actual or asserted claim of negligence, willful misconduct or breach of contract. Guarantors further agree to maintain primary and noncontributing Products Liability Insurance of not less than U.S. $5,000,000.00 per
occurrence, Combined Single Limit (Bodily Injury and Property Damage) including AmerisourceBergen Corporation and its subsidiary companies and their successors as Additional Insureds, including a Broad Form Vendors Endorsement, with provision for at
least 30 days’ prior written notice to the Additional Insureds in the event of cancellation or material reduction of coverage, and upon request promptly submit satisfactory evidence of such insurance. All insurance coverage must be with a
carrier and in a form acceptable to AmerisourceBergen Corporation, at its sole discretion, including any deductible or self-insurance risk retained by Guarantors. In combination with significant excess liability insurance, any retained risk must be
commercially reasonable, actuarially sound and acceptable to AmerisourceBergen Corporation, at its sole discretion. Each Guarantor warrants that its assets are sufficient to cover any self-insurance liability it assumes under this Agreement.
Provisions in this Continuing Guaranty and Indemnification Agreement are in addition to, and not in lieu of, any terms set forth in any purchase orders accepted by Guarantors or any separate agreement entered into between AmerisourceBergen
Corporation or any of its subsidiaries or their successors and Guarantors. In the event of any conflict between the language of such other documents and the language set forth herein, the language herein shall be controlling. 

 

			
	 
		
	By:	 	 /s/ Joseph K. Belanoff, M.D.

		
	Name:	 	 Joseph K. Belanoff, M.D.

		
	Title:	 	 CEO

		
	Date:	 	 4/27/11

  
 Page 24

 EXHIBIT B 
 CUSTOMER SERVICES 
 ICS shall perform the following Services on and after
the Program Launch Date during the Term of the Agreement: 
 1. ICS, as agent of the Company, will develop, operate and maintain an Integrated
Access Center (“Access Center”) to manage the comprehensive distribution Services related to Products described herein (“Customer Services”) for the Company. ICS agrees to develop the Access Center and provide the Customer
Services for the fees listed in Schedule B. 
 2. The Access Center includes the following: 

 

	 	2.1	A fully-integrated telecommunications and information system that will capture and manage key data from each Customer requesting information or specific services
relating to Products; 

  

	 	2.2	A toll-free Company-dedicated telephone and fax number solely for the Access Center, with all costs being the Company’s responsibility; 

 

	 	2.3	The capability to handle queries about Products related to order processing and account management; and 

 

	 	2.4	The capability to triage queries. 

 3. ICS, as
agent of the Company, will retain, train and manage appropriate staff personnel to operate the Access Center. Responsibilities of Access Center personnel will be to: 
  

	 	3.1	Receive orders via Electronic Data Interchange (“EDI”), facsimile, email, mail or telephone, and (b) be available from 8:00 a.m. to 5:00 p.m. (Central)
to receive orders or triage calls to the Company as necessary; 

  

	 	3.2	Receive EDI orders from the Company or its Customers. Upon receipt, ICS will: 

 

	 	3.2.1	Verify that product order file processed from customer and into ICS’ ERP system; 

 

	 	3.2.2	Review EDI order processing error logs and communicate any non-processed orders and reasons to the Company or its Customers; and 

 

	 	3.2.3	Take appropriate action based on direction from the Company to resolve any issues and re-enter orders or order files into the ERP for processing;

  

	 	3.3	Generate and issue packing slips for the sale of Products sold under this Agreement; 

 

	 	3.4	Manage the process of issuing Product return authorizations and Product destruction authorizations in accordance with the Company’s policies that have been
provided to ICS, and coordinate shipment of Product for destruction; 

  

	 	3.5	Set up customer accounts for Customers eligible to purchase from the Company according to parameters provided by the Company, and the Company will periodically supply
ICS with its written criteria, as amended from time to time, for all Customer eligibility; and 

  
 Page 25

	 	3.6	At the Company’s prior written request, verify that such Customers meet the Company’s eligibility criteria by: 

 

	 	3.6.1	Credit verification using approved agencies and establishment of credit limits based on the Company’s guidance; 

 

	 	3.6.2	Verification of licenses (including verification of DEA and state controlled substances, regulatory licenses and registrations when filling orders of controlled
substances); and 

  

	 	3.6.3	License verification using the NTIS database augmented by a copy of the Customer license if necessary; and 

 

	 	3.7	Obtain Proofs of Deliveries (PODs) for the Company. 

 4. Order allocations encompass any inbound orders to ICS that need to have original conditions reviewed and/or manipulated as opposed to allowing the order to flow freely through the order process system.
All allocated orders shall be filled in accordance with the Company’s written instructions. 
 5. An order is defined as a shipment to a
unique address that leaves the distribution center, regardless of the number of cartons or packages that constitute that shipment and/or the number of inbound requests for such order. 
 6. The following services are not a part of Customer Services normally provided in the Access Center: 
  

	 	6.1	Product substitution relating to backorder management: 

  

	 	6.2	Stock allocation of Product to the Company’s Customer base: 

  

	 	6.3	Arranging for the re-distribution of Product within the Company’s Customer base; or 

 

	 	6.4	Any services not identified in paragraphs 1 through 3 of this Exhibit B. 

  
 Page 26

 EXHIBIT C 
 WAREHOUSING AND INVENTORY MANAGEMENT SERVICES 
 ICS shall perform the
following Services on and after the Program Launch Date during the Term of the Agreement: 
 1. ICS will warehouse and inventory Products at the
ICS Facility. 
 2. ICS will visually inspect each shipment of Product for external container or package damage or loss in transit (based upon
records provided to ICS by the Company) 
 3. ICS will promptly notify the Company upon ICS’s discovery of any damage or loss to Product.

 4. ICS will quarantine Product upon receipt and will release Product to salable inventory status within twenty-four (24) hours of
written authorization from the Company. 
 5. ICS will store all Product in compliance with current good manufacturing practice regulations and
guidelines and other requirements of the FDA, the U.S. Drug Enforcement Administration (including maintaining required registrations, licenses and other authorizations, observing all DEA security standards and timely filing any necessary ARCOS
reports and other DEA forms, including DEA form 222), all other applicable Requirements of Law and in accordance with the Company’s written instructions, if any. 
 6. The Company will pay all costs, charges, expenses and import and export duties for delivery and transportation of Product to and from an ICS Facility; provided that ICS shall be responsible for
the costs of any transfers of Product from one ICS Facility to another ICS Facility that are initiated by ICS and not requested by the Company. 

  
 Page 27

 EXHIBIT D 
 DISTRIBUTION SERVICES 
 ICS shall perform the following Services on and
after the Program Launch Date during the Term of the Agreement: 
 1. Distribution. ICS shall provide the following distribution tasks:

  

	 	1.1	ICS shall use its best efforts to ensure that Products will be distributed by trained personnel either in corrugated boxes obtained by ICS or in the corrugated boxes in
which Products are packaged by the manufacturer. 

  

	 	1.2	ICS shall use it best efforts to ship Products within [***] of receipt of orders by ICS unless otherwise specified under the terms of this Agreement. ICS will not be
required to ship within [***] if the aggregate of the orders transmitted to ICS on a single day exceed the number of average daily orders received by ICS for the previous [***]of the total of such orders. ICS will ship Product to the [***] will ship
out of the ICS Facility on the same day the order is received. 

  

	 	1.3	ICS shall ship Veterans Administration and other government orders direct or to the designated PPV (Preferred Pharmaceutical Vendor). 

 

	 	1.4	ICS shall distribute bulk shipments by a designated carrier using carrier bulk shipment terms. 

 

	 	1.5	ICS shall use its best efforts to ensure that Products are distributed on a FEFO (first expired/first out) basis unless otherwise directed by the Company in writing.

  

	 	1.6	At the prior written request of the Company, ICS shall deliver Products as a drop ship to Customers and billed to the designated wholesaler. 

 

	 	1.7	ICS shall use its best efforts to ensure that non-EDI orders received by ICS during standard warehouse hours of shipping (currently M-F 8:00 a.m. to 3:00 p.m. Eastern,
except holidays) will be filled [***]. ICS shall also use its best efforts to ensure that orders received after this agreed upon cut-off time will be processed no later than the next business day. ICS shall use its best efforts to ensure that EDI
orders will be processed within [***] to ICS. ICS will not be obligated to fulfill order within such time periods if orders received by ICS on a single day exceed the number of average daily orders received by ICS for the previous [***] of the total
of such orders. 

  

	 	1.8	At the Company’s request, ICS shall provide a “Rush Order” service for specific order or orders to be processed and shipped the same day; provided
however, that such services are dependent on ICS's ability to perform based upon order receipt time, ICS personnel, and transportation carrier availability. Such orders shall be subject to the Company’s payment of the additional fees pursuant
to Schedule B. 

  

	 	1.9	 At the Company’s request, ICS shall provide “Emergency Order” services, defined as any order received outside of scheduled working hours
(currently M-F 

  
 Page 28

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	
8:00 a.m. to 5:00 p.m. Eastern Time) requiring ICS staff to return to the ICS Facility to process the order within the same day. Such Emergency Order services will be subject to additional fees
pursuant to Schedule B. ICS shall clearly identify any such orders to the Company at the time of the Company’s request. 

 2. Inventory. ICS will be responsible for the following inventory tasks: 
  

	 	2.1	ICS shall receive Products from the Company or a Company designee. 

  

	 	2.2	ICS shall ensure that any end of lot discrepancies evidenced by a difference in physical to book inventory as noted during Product distribution will trigger inventory
counts and reconciliation by ICS to verify and determine, where possible, the cause for the discrepancy. 

  

	 	2.3	ICS shall provide the Company, at ICS’s expense, [***] physical product inventory per calendar year and routine cycle counts. ICS shall perform additional physical
product inventories upon the Company’s request and for an additional labor charge. Any such additional physical inventory requested by the Company will be scheduled based upon a written request from the Company and a mutually agreed upon
inventory date. 

  

	 	2.4	ICS shall obtain any required packaging materials for distribution the cost of which shall be passed through to the Company pursuant to Schedule B.

  

	 	2.5	ICS shall pay all labor costs for warehouse personnel providing the Services. 

 

	 	2.6	ICS shall provide tracking for all shipments as required by the Company; 

  

	 	2.7	ICS shall pay for all security costs for the ICS Facility and any other warehouse locations where Products may be stored in accordance with the terms of this Agreement.

  

	 	2.8	ICS shall process returns within seven business days of receipt at the ICS Facility. 

 

	 	2.9	ICS shall ship outdated/damaged Products to a site reasonably designated by the Company for disposal. All transportation and destruction costs will be borne by the
Company pursuant to Schedule B. 

  

	 	2.10	ICS shall not responsible for maintaining inventory levels for Product fulfillment. 

 3. Product Title. The Company will at all times retain title to all of Products under this Agreement. 
 4. Exclusions. The following services will not be provided by ICS or included as Distribution Services under the terms of this Agreement: 

 

	 	4.1	Processing of Department of Transportation hazardous materials. 

  

	 	4.2	Re-stacking of inbound Products required at the ICS Facility. 

  

	 	4.3	Any other special labeling or packaging required for Products on or for shipments leaving the ICS Facility. 

  
 Page 29

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT E 
 WAREHOUSING AND DISTRIBUTION OF SAMPLE PRODUCTS ( IF APPLICABLE) 
 ICS shall perform the
following Services on and after the Effective Date during the Term of the Agreement. The parties’ respective obligations are set forth below. 
 1. Sample Products. “Sample Products” shall mean [INSERT PRODUCT NAME], which is not intended to be sold and shall be re-labeled as such and is given to customers free of charge to promote
sales. 
 2. Storage and Shipment of Samples. ICS will warehouse, inventory and distribute Samples and Free Goods consistent with standards for
warehousing, inventory and distributing Services under Exhibit B. ICS will distribute Samples by mail or common carrier. ICS’s obligation to perform Services is conditioned on the Company’s performance of tasks as specified under Exhibit
B. 
 3. Re-Labeling of Sample Products. ICS shall perform re-labeling services reasonably requested by Company and consistent with all
Requirements of Law. ICS shall ensure that each Sample Product distributed by ICS bears a label that includes one of the following statements: “Sample,” “Not for sale,” or “Professional courtesy package.” ICS shall
include on the label of each Sample Product and on the outside container or packaging (if any) an identifying lot or control number that will permit the tracking of the distribution of each unit of Sample Product. 

4. Recipients. For purposes of sending samples the Company will, from time to time, provide ICS with a current and accurate list of recipients authorized
to receive Sample Products (“Recipients”), including additions, corrections, and deletions. At a minimum, the list will include the name and ship-to address of each Recipient. ICS will adhere to its standard operating procedures for
distribution of Sample Products to Recipients, as well as all Requirements of Law, including without limitation the PDMA, pertaining to distribution of samples to Recipients. 
 4.1 Physician Recipients. Prior to each delivery of Sample Product by ICS to a Physician Recipient, the Company will provide ICS with a completed sample request form in a form mutually agreed upon by the
Parties, which shall be signed by the physician making the request (the “Sample Request Form”). The Sample Request Form will contain the following information: 
 4.1.1 the applicable state license or authorization number (or DEA number where a controlled substance is requested) for the physician authorized to receive Samples Products; 

4.1.2 the name, address, professional title and signature of the physician making the request; 

4.1.3 the proprietary or established name and strength of the Sample Product requested; 

4.1.4 the amount of Sample Product requested; 
 4.1.5 the date of the request; 
 4.1.6 the full names of the Company and ICS; and

 4.1.7 any other information required by § 203.30 or other applicable law for the distribution of Sample Products to a
physician. 

  
 Page 30

 4.2 Pharmacy or Hospital Recipients. Prior to each delivery of Sample Product by ICS to
pharmacy or hospital Recipient, the Company will provide ICS with a completed Sample Request Form, which is signed by the physician making the request. The Sample Request Form shall contain all of the information listed in Section 4.1 above and
shall also include the name and address of the pharmacy or hospital to which the Sample Product shall be delivered. 
 5. Receipts for Sample
Products. Upon delivery of the Sample Product, ICS shall obtain a receipt that contains the following information: 
 5.1 Physician Recipient.
If the Recipient is a physician, the receipt will include at a minimum: (i) the signature of the physician or the physician’s authorized designee acknowledging delivery of the Sample Product; (ii) the physician’s name, address,
professional title; (iii) the proprietary or established name and strength of the Sample Product; (iv) the quantity of the Sample Product delivered; (v) the date of delivery; and (vi) any other information required by law and/or
regulation. 
 5.2 Pharmacy or Hospital Recipients. If the Recipient is a Pharmacy or Hospital, the receipt will include at a minimum:
(i) the name and address of the licensed physician requesting the Sample Product; (ii) the name and address of the pharmacy or hospital designated to receive the Sample Product; (iii) the name, address, professional title and
signature of the person acknowledging delivery of the Sample Product; (iv) the proprietary or established name and strength of the Sample Product; (v) the quantity of the Sample Product requested; and (vi) the date of delivery.

 6. Reconciliation of Sample Product Requests and Receipts; Losses. ICS shall be responsible for reconciling sample requests, receipts and
inventory of Sample Products as mutually agreed by the parties and consistent with all Requirements of Law. ICS shall report all discrepancies, thefts and losses involving Sample Products to Company promptly. Company shall develop an appropriate
definition for “Significant Loss,” and shall be responsible for determining whether any discrepancy, theft or loss constitutes a Significant Loss. In the event that Company determines that a Significant Loss exists, Company shall notify
the FDA of the loss consistent with PDMA requirements. 
 7. Record Keeping Requirements. The Company and ICS will create and maintain all
applicable forms and records required by all Requirements of Law applicable to warehousing and distribution of Samples and Free Goods including PDMA, Rules and Controlled Substance Laws. Prior to the distribution of any Samples or Free Goods, the
Company and ICS will identify in a separate written procedure the specific forms and records each will maintain so that distribution of Samples and Free Goods will comply with all Requirements of Law. The Company and ICS will permit the other, upon
reasonable advance notice, to audit and inspect all such forms and records it creates or maintains in distributing Samples Products. The Company and ICS will cooperate and assist with, and will provide the other with access to and copies of, such
forms and records as may be useful in responding to, regulatory agency inspections or requests for such forms or records. 

  
 Page 31

 EXHIBIT F 
 MARKETING MATERIALS FULFILLMENT SERVICES ( If applicable) 
 ICS will
warehouse and manage distribution of Product and clinical and marketing materials that are sent to the Company's authorized personnel (the “Company Representatives”) on and after the Program Launch Date during the Term as follows:

  

	1.	The Company will develop and provide to ICS all materials for use in the Access Center. 

 

	2.	The Company will provide ICS with such bulk clinical and marketing materials in mutually agreeable packaging configuration shrink-wrapped packages designated as one
“SKU” (Stock Keeping Unit). Whenever possible, the Company will direct its other vendors to adopt specifications and coding systems that are currently being utilized in ICS’s Facility, with the SKU clearly marked with Product code to
be used by ICS. 

  

	3.	ICS will charge the Company the fees in Schedule B for the storage of marketing materials. 

 

	4.	ICS will ship orders for marketing materials by ground unless otherwise specified in writing by the Company. 

 

	5.	Upon prior written approval from the Company, ICS will begin responding to requests for marketing materials, which requests will be directed to ICS by the Company
Representatives by facsimile or electronic mail. In addition, ICS will, upon written request of the Company, ship marketing materials to medical conventions, back to the Company or the Company’s Representatives, care givers and other healthcare
providers, for fees in Schedule B. 

  

	6.	The Company will provide new product specifications as outlined in the “Product Set Up Sheets” to ICS at least five business days prior to product receipt at
the warehouse. 

  

	7.	The Company will ensure that Product is configured in the minimum order quantity for shipment purposes. 

 

	8.	Services not covered under the terms of this Agreement include: 

  

	 	8.1	Any marking required at ICS’s Facility for Product identification purposes; and 

 

	 	8.2	Processing or re-stocking marketing materials returned from trade shows. 

  

	 	8.3	Repackaging of marketing materials to meet ICS configuration requirements. 

  
 Page 32

 EXHIBIT G 
 CONTRACT ADMINISTRATION AND CHARGEBACKS PROCESSING 
 ICS is licensed to
utilize BPI Contracts software developed by BPI Technologies Corporation to provide contract administration and chargeback processing services. ICS shall perform the following Services on and after the Program Launch Date during the Term of the
Agreement: 
 1. Contract Administration. ICS shall enter into the BPI Contracts application key demographic information, membership, and
pricing arrangements, as provided by the Company, as negotiated between the Company and its key government and non-government contract accounts, including DOD and VA. ICS shall assist the Company in managing information for such accounts, but shall
have no liability for the timeliness, accuracy or reliability of the information provided by the Company under this Section. 
 2. Chargeback
Processing. ICS will process debit memo submissions from wholesalers for wholesaler contract sales pricing reconciliation. 
  

	 	2.1	Reconciliation is based upon verification of the submitted wholesaler data against contract administration data. Results of this verification are:

  

	 	2.1.1	Reconciliation reporting; and 

  

	 	2.1.2	Credit Memo generation. 

  

	 	2.2	Submissions by wholesalers will be either paper or electronic (EDI). 

  

	 	2.2.1	Paper - Processing time for paper submissions will [***] 

  

	 	2.2.2	EDI - Processing time for EDI submissions will be [***] 

  

	 	2.2.3	These times do not apply to new or newly acquired Products for a period of [***]. 

 3. Rebates. ICS will provide documentation for rebates to be paid by the Company on a quarterly basis. ICS will also provide the Company with reports, in a format agreed upon by the parties,
including pricing information for AMP and FAMP reports, and which otherwise allow the Company to monitor purchasing activity by its key accounts. 

  
 Page 33

  

 [***] Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT H 
 ACCOUNTS RECEIVABLE MANAGEMENT AND CASH APPLICATIONS 
 ICS shall perform
the following Services on and after the Program Launch Date during the Term of the Agreement: 
 1. ICS will manage all accounts receivable
transactions related to the Company managed distribution programs for Product. The Company will establish a lock box at a financial institution of its choosing (the “Financial Institution”). Payments from Customers will be directed to the
address of the lock box. The Financial Institution will sweep the lock box daily and deposit payments into the Company’s operating account. The Financial Institution will forward copies of all payment transactions to ICS for cash application
purposes. ICS and the Company will jointly determine the following: 
  

	 	1.1	Credit policy 

  

	 	1.2	Class of trade designations 

  

	 	1.3	Terms and conditions 

  

	 	1.4	License requirements 

  

	 	1.5	Dunning process for past due accounts 

  

	 	1.6	Reporting requirements 

 2. ICS will provide
comprehensive accounts receivable management services in conformance with ICS’s standard operating procedures and the Company’s collection policies as they apply to: 

 

	 	2.1	Invoicing (prepare and mail Customer invoices) 

  

	 	2.2	Cash application 

  

	 	2.3	Reconciliation of daily lock box deposits 

  

	 	2.4	Credit hold/release processing 

  

	 	2.5	Change to Customer credit limits per the Company’s approval 

 Credit reports: 
  

	 	2.5.1.	Experian 

  

	 	2.5.2	D & B 

  

	 	2.6	Return authorization credits 

  

	 	2.7	Credit and re-bills 

  

	 	2.8	Reconciliation of accounts receivable to chargebacks 

 3. ICS will adhere to state and federally mandated good credit and collection practices established jointly by ICS and the Company such as: 

 

	 	3.1	On-line details of calls 

  

	 	3.2	Call list of past due invoices 

  

	 	3.3	Past due reminder letters 

  

	 	3.4	Research and collection of unauthorized deductions 

  

	 	3.5	The Company approved write-offs 

  
 Page 34

 EXHIBIT I 
 FINANCIAL MANAGEMENT SERVICES 
 ICS shall perform the following Services on
and after the Program Launch Date during the Term of the Agreement: 
 1. ICS will provide monthly reconciliation of all financial transactions
related to the Company managed distribution program for Product as follows: 
  

	 	1.1	Month end close 

  

	 	1.2	Reconciliation of cash, cash discounts and accounts receivable 

  

	 	1.3	Inventory roll over 

  

	 	1.4	Reconciliation of inventory adjustments 

  

	 	1.5	Reconciliation of goods received 

  

	 	1.6	Reconciliation of sales and cost of goods sold 

  

	 	1.7	Reconciliation of returns and cost of goods returns 

 2. ICS will provide on a monthly basis (or other agreed upon period), the following financial reports: 
  

	 	2.1	Trial Balance 

  

	 	2.2	Cash Application Summary 

  

	 	2.3	Accounts Receivable Reports 

  

	 	2.4	Inventory Reports 

  

	 	2.5	Sales Reports 

  

	 	2.6	Cash Discounts Report 

  
 Page 35

 EXHIBIT J 
 IT SERVICES 
 ICS shall perform the following Services on and after the
Program Launch Date during the Term of the Agreement: 
 1. Application Software. ICS shall maintain a license to utilize ERP software
developed by International Business Systems to provide Distribution and Financial Services to the Company. 
 2. Access. ICS shall ensure
that access to the DataMart will be available to the Company Monday through Friday from 7:00 a.m. – 7:00 p.m. (Central) except for those holidays recognized by ICS (“Holidays”), a listing of which will be mutually agreed to by the
Company and ICS. ICS will contact the Company with reasonable notice of any non-availability of the DataMart due to routine or non-routine system maintenance undertaken by ICS. “DataMart” shall be defined as the repository of information
available to ICS regarding Products and related standard reports, including but not limited to daily inventory reports and inventory adjustments. 
 3. On-Call Support. ICS shall maintain an on-call support line for answering Company questions, receiving requests for correction of errors and providing consulting services relative to the
functionality and usage of the DataMart. The support line will be available from 8:30 a.m. – 5:00 p.m. (Central) except for Holidays. 
 4.
Training. ICS shall provide user documentation and training for DataMart through data dictionaries of DataMart; provided, however, that ICS shall have no obligation to provide Crystal Training and licenses to utilize crystal reports to
the Company. 
 5. Back-Ups. ICS shall perform back-up of all the Company transactions at the end of each working day. Such back-up will
be performed at a scheduled time each day and will use an IBM utility product to copy all ICS’s the Company data on a media selected by ICS. 
 6. Data Management and Reporting. ICS shall provide the Company with standard reports as may be reasonably requested by the Company from time to time. ICS has also developed a set of
standard data file extracts that cover distribution and financial activity. Frequency for report or data file creation is in part based on functional requirement but may be daily, weekly, monthly or on demand. If customization is needed, the Company
and ICS will jointly and reasonably determine the data elements and formats to be included in custom reports, as well as their frequency and data files. Mutually agreed-upon standard reports and files are included in the pricing provided under this
Agreement. Additional charges will apply to special reports and data files created based upon hourly programming charges as listed in Schedule B for creation of specialized reports. The Company will be responsible for hardware or software
costs directly and for fees listed in Schedule B. 
 7. Transfer Protocol. ICS will make available to the Company data in the form
of electronic files on a detail or summary basis that reflects the operational activity in the Company’s DataMart or CARS/IS environment. The frequency of the data file availability may be event based, daily, weekly or monthly. Certain timing
restrictions apply based on type of data. Conversely ICS will receive files from the Company for the purpose of file building, file maintenance or order processing. The data may be delivered in one of four methods: 1) Cyclone Encrypted or PGP
encrypted, 2) Secure Website, 3) E-mail (emergency only) or 4) Electronic Data Interchange: 
 8. System Disaster Recovery. ICS shall
maintain in place disaster-relief plans consisting of disaster recovery procedures, telecommunications switch over during disaster or emergency period, and AS/400 System switch over during disaster or emergency period (collectively, “Disaster
Plans”). ICS will maintain the Disaster Plans during the Term. 

  
 Page 36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]